**Session Title:** Costs of Cancer Care: Affordability, Access, and Policy

**Session Type:** Education Session

**Time:** 8:00 AM - 9:15 AM

**Location:** E Hall D1

- Reducing the Costs of Cancer Care: Bending the Curve and How
  
  *Thomas J. Smith, MD (Chair)*

- Delivering Affordable Cancer Care
  
  *Richard Sullivan, PhD, MBBS*

- Comparative Effectiveness and Costly New Drugs
  
  *Sean R Tunis, MD, MSc*

---

**Session Title:** Ethical Challenges of Health Care Reform for Oncology Providers: A Debate

**Session Type:** Education Session

**Time:** 8:00 AM - 9:15 AM

**Location:** E353

- The Core Elements of Patient Protection and Affordable Care Act (PPACA) and Their Relevance to the Delivery of High Quality Cancer Care
  
  *Beverly Moy, MD (Chair)*

- Ethical Challenges in the Practice of Oncology Raised by U. S. Health Care Reform
  
  *Jeffrey M. Peppercorn, MD, MPH*

- Moderator of Panel Discussion in Second Part of Session
  
  *Amy Pickar Abernethy, MD*

---

**Session Title:** Molecular and Genomic Diagnostics in Pediatric Oncology: When and How They Should Be Implemented

**Session Type:** Education Session

**Time:** 8:00 AM - 9:15 AM

**Location:** S504

- Does Genotype Define Disease: The Case of Pediatric Sarcomas
  
  *Stephen L. Lessnick, MD, PhD (Chair)*

- When Is Genomic Stratification Ready for Prime Time: Lessons from Medulloblastoma
  
  *Kenneth J. Cohen, MD, MBA*

- Implementation of and Issues Related to Genomic-Based Diagnosis for Treatment and Stratification of Pediatric Cancer
  
  *John M. Maris, MD*

---

**Session Title:** New Looks and Challenges for Cooperative Groups

**Session Type:** Education Session

**Time:** 8:00 AM - 9:15 AM

**Location:** S404

- Community Needs from the Cooperative Groups
  
  *Stephen S. Grubbs, MD (Chair)*

- Impact of New Cooperative Group Structure on Clinical Trials
  
  *Robert Leo Comis, MD*

- Successful Integration of Cooperative Groups: The COG Example
  
  *Gregory H. Reaman, MD*

---

**Session Title:** New Options, New Questions: How to Select and Sequence Therapies for Metastatic Melanoma

**Session Type:** Education Session
Time: 8:00 AM - 9:15 AM
Location: E354b

- Immunotherapies in Melanoma: When? Which One? What Dose?
  Michael B. Atkins, MD (Chair)
- BRAF-Mutant Metastatic Melanoma: Is a BRAF Inhibitor Always First-Line Therapy?
  Keith T. Flaherty, MD
- Understanding and Treating BRAF Wild-Type Metastatic Melanoma
  Jeffrey Alan Sosman, MD

---

Session Title: Physician Wellness: Coping with Repetitive Loss and Work-Related Stress
Session Type: Education Session
Time: 8:00 AM - 9:15 AM
Location: S100bc

- Repetitive Loss: Coping with Your Grief
  Teresa Gilewski, MD
- So You Are Stressed? Impacts on Individual Physicians and the Workforce
  Joshua Hauser, MD
- What Can Be Done to Decrease Stress in Oncology Providers?
  Michael Fisch, MD, MPH (Chair)

---

Session Title: Toward Successful Targeting of the PI3 Kinase Pathway in Cancer
Session Type: Education Session
Time: 8:00 AM - 9:15 AM
Location: S406

- PI3 Kinase in Cancer: From Biology to the Clinic
  Paul Workman, BSc, PhD, DSc (Chair)
- PI3K Inhibition in Chronic Lymphocytic Leukemia: Bringing Pathway Inhibition to the Bedside
  John C. Byrd, MD
- PI3K Inhibition in Breast Cancer: Mechanisms of Sensitivity and Resistance
  Carlos L. Arteaga, MD

---

Session Title: Paraganglioma: Genetics in Action - Ticketed Session
Session Type: Meet the Professor Session
Time: 8:00 AM - 9:15 AM
Location: E451a

- Paraganglioma and Succinate Dehydrogenase
  Joshua David Schiffman, MD

---

Session Title: How and When Molecular Markers Should Be Used in a Neuro-oncology Practice - Ticketed Session
Session Type: Clinical Problems in Oncology Session
Time: 8:00 AM - 9:15 AM
Location: E451b

- Point/Counterpoint: Molecular Profiling Is Ready or Near-Ready for Use in Clinical Practice
  Ingo K. Mellinghoff, MD (Chair)
- Point/Counterpoint: Molecular Markers Are of Biologic Importance But Not Yet Ready for Use in Clinical Practice for Treatment-Related Decisions
  Martin J. Van Den Bent, MD

---

Session Title: Diabetes and Cancer
Session Type: Clinical Science Symposium
Time: 8:00 AM - 9:30 AM
Location: S100a

- Chair
  Pamela Jean Goodwin, MD, MSc
• Diabetes, related factors, and breast cancer risk. (Abstract #1509)
  
  Peter Boyle

• Discussion
  
  Bendix Carstensen, MSc

• Meta-analysis of cancer risk among users of insulin glargine. (Abstract #1510)
  
  Alice Koechlin

• Changes in glucose, insulin, and insulin resistance from presurgery to post adjuvant treatment for breast cancer. (Abstract #1511)
  
  Emer M. Guinan

• Discussion
  
  Derek Leroith, MD, PhD

• Discussion
  
  Pamela Jean Goodwin, MD, MSc

---

**Session Title:** Emerging New Targets and New Drugs in Non-small Cell Lung Cancer  
**Session Type:** Clinical Science Symposium  
**Time:** 8:00 AM - 9:30 AM  
**Location:** E Hall D2

• Co-Chair
  
  Leora Horn, MD, MSc

• Co-Chair
  
  Jean-Charles Soria, MD, PhD

• Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. (Abstract #7508)
  
  Alice Tsang Shaw

• Discussion
  
  Gregory J. Riely, MD, PhD

  
  Julie R. Brahmer

• Discussion
  
  Giuseppe Giaccone, MD, PhD

• Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens. (Abstract #7510)
  
  Marzia Capelletti

• Discussion
  
  William Pao, MD, PhD

---

**Session Title:** Mutation Analysis for Cancer Diagnosis and Targeted Therapy  
**Session Type:** Clinical Science Symposium  
**Time:** 8:00 AM - 9:30 AM  
**Location:** E354a

• Co-Chair
  
  Andrea P. Myers, MD, PhD

• Co-Chair
  
  Daniela Matei, MD

• Impact of metformin use on risk of recurrence in high-grade endometrial cancers. (Abstract #5009)
  
  Emily Meichun Ko

• Discussion
  
  Matthew Vander Heiden, MD, PhD
• Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC). (Abstract #5010)
  
  Helen Mackay

• Discussion
  
  Andrea P. Myers, MD, PhD

• KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. (Abstract #5011)
  
  Alexi A. Wright

• Discussion
  
  Robert Kurman, MD

**Session Title:** New Paradigms for Hormone Therapy in Prostate Cancer

**Session Type:** Clinical Science Symposium

**Time:** 8:00 AM - 9:30 AM

**Location:** E Arie Crown Theater

• Co-Chair
  
  Michael Roger Harrison, MD

• Co-Chair
  
  Ajjai Shivaram Alva, MBBS, MS

• Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #LBA4518)
  
  Charles J. Ryan

• Discussion
  
  Susan Halabi, PhD

• Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (Abstract #4519^)
  
  Johann Sebastian De Bono

• Discussion
  
  William Kevin Kelly, DO

• Neoadjuvant androgen pathway suppression prior to prostatectomy. (Abstract #4520)
  
  Elahe A. Mostaghel

• Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. (Abstract #4521)
  
  Mary-Ellen Taplin

• Discussion
  
  Joshi J. Alumkal, MD

**Session Title:** Designing Clinical Trials for Older Patients: Regulatory, Community, and Advocacy Perspectives

**Session Type:** Special Session

**Time:** 8:00 AM - 11:00 AM

**Location:** S103

• Co-Chair
  
  Hyman Bernard Muss, MD (Co-Chair)

• Co-Chair
  
  Arti Hurria, MD (Co-Chair)

• Clinical Trials for Older Patients in NCI-sponsored Clinical Treatment Trials
  
  Margaret M. Mooney, MD, MBA

• Geriatric Oncology: EU Regulatory Perspective and Initiatives
  
  Iordanis Gravanis, MD, PhD
• Community Enrollment of Geriatric Oncology Patients within Clinical Trials  
  *James Alfred Wallace, MD*

• Designing Clinical Trials for Older Patients: A Road to What?  
  *Beverly Canin*

• Rethinking Observational Cohort Studies for Geriatric Oncology  
  *Supriya Gupta Mohile, MD, MS*

---

**Session Title:** Developmental Therapeutics - Clinical Pharmacology and Immunotherapy  
**Session Type:** Poster Discussion Session  
**Display Time:** 8:00 AM - 12:00 PM  
**Display Location:** S405  
**Discussion Time:** 12:00 PM - 1:00 PM  
**Discussion Location:** S406

- **Chair**  
  *Theodore Logan, MD*

Brd. 2
- Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. (Abstract #2514)  
  *Holbrook Edwin Kohrt*

Brd. 3
- Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. (Abstract #2515)  
  *Maria Teresa Solomon*

Brd. 4
- Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. (Abstract #2516)  
  *Gayle S. Jameson*

Brd. 5
- A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. (Abstract #2517)  
  *Philip M. Arlen*

- **Discussion**  
  *Padmanee Sharma, MD, PhD*

Brd. 6
- Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma. (Abstract #2518)  
  *Shigehisa Kitano*

Brd. 7
- Assessment of a novel immunological biomarker SNP panel from a phase III trial of Bacillus Calmette-Guérin (BCG) adjuvant treatment in stage III melanoma patients. (Abstract #2519)  
  *Connie Ging Ting Chiu*

Brd. 8
- Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. (Abstract #2520^)  
  *Jianjun Gao*

Brd. 9
- The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade. (Abstract #2521)  
  *Margaret Callahan*
• Immune responses and association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910. (Abstract #2522)
  *Sabrina Kuttruff*

• Discussion
  *Stephen Maxted Ansell, MD, PhD*

• Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. (Abstract #2523)
  *Sebastian Ochsenreither*

• Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients. (Abstract #2524)
  *Natalia N. Petenko*

• CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma. (Abstract #2525)
  *Gerald P. Linette*

• Interim analysis of a phase II randomized clinical trial of samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. (Abstract #2526)
  *Christopher Ryan Heery*

• EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial. (Abstract #2527)
  *Tania Crombet Ramos*

• Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL). (Abstract #2528)
  *Kieron Dunleavy*

• Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine. (Abstract #2529)
  *Raetasha Sheavette Dabney*

• Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. (Abstract #2530)
  *Jesus Corral Jaime*

• Response to epidermal growth factor vaccine in patients with metastatic non-small cell lung cancer (NSCLC) after progressing to first-line therapy. (Abstract #2531)
  *Diego Venegas*

• Discussion
  *Renier J. Brentjens, MD, PhD*

• Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report. (Abstract #2532)
  *Steven M Belknap*
• Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study. (Abstract #2533)  
  Jan Hendrik Beumer

• A first-in-human, phase I safety and pharmacokinetic study of genz-644282, a non-camptothecin topoisomerase I inhibitor, in patients with advanced solid tumors. (Abstract # 2534)  
  Hyo S. Han

• Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (Abstract #2535)  
  Min Zhu

• Pharmacological interactions of TKIs with the P-gp drug transport protein. (Abstract #2536)  
  Sandra Roche

• Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving third-line panitumumab-irinotecan: A GERCOR ancillary study. (Abstract #2537^)  
  Marie-Christine Etienne-Grimaldi

• Discussion  
  Aung Naing, MD

Session Title: Genitourinary (Nonprostate) Cancer  
Session Type: Poster Discussion Session  
Display Time: 8:00 AM - 12:00 PM  
Display Location: E450a  
Discussion Time: 12:00 PM - 1:00 PM  
Discussion Location: E Arie Crown Theater  
  • Co-Chair  
    Hans J. Hammers, MD, PhD  
  • Co-Chair  
    Maria De Santis, MD

• Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. (Abstract #4522)  
  Gregory Russell Pond

• Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. (Abstract # 4523)  
  Arlene O. Siefker-Radtke

• Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. (Abstract #4524)  
  Matt D. Galsky

• Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC). (Abstract #4525)  
  Benjamin Maughan
• Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study. (Abstract #4526)
  
  Elizabeth R. Plimack

• Defining the genetic basis of everolimus sensitivity in metastatic bladder cancer (MBC) by whole-genome sequencing (WGS). (Abstract #4527)
  
  Gopa Iyer

• Discussion
  
  Jonathan E. Rosenberg, MD

• Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors. (Abstract #4528)
  
  Hink Boer

• The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen. (Abstract #4529)
  
  Waleed Badreldin

• Five years into the national second-opinion project of the German Testicular Cancer Group (GCTSG): Impact on guideline implementation and the quality of care for testicular cancer patients. (Abstract #4530)
  
  Friedemann Zengerling

• Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials. (Abstract #4531)
  
  Peter S. Grimison

• Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts). (Abstract #4532)
  
  Darren Richard Feldman

• Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). (Abstract #4533)
  
  Yago Nieto

• A retrospective analysis of patients with intermediate-risk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010. (Abstract #4534)
  
  Costantine Albany

• Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo). (Abstract #4535)
  
  Ben Tran

• Discussion
  
  Kim Allyson Margolin, MD
An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. (Abstract #4536)

Daniel Yick Chin Heng

Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study. (Abstract #LBA4537)

Shukui Qin

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium. (Abstract #4538)

Wanling Xie

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results. (Abstract #4539)

Maurice Stephan Michel

The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mRCC patients: An integrated analysis of the TARGET and RECORD phase III trials data. (Abstract #4540)

Charles Ferte

PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT). (Abstract #4541)

Michele Milella

Discussion

Ana M. Molina

Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition. (Abstract #4543)

Mark M Pomerantz

Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology. (Abstract #4544^)

Youngil Koh

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. (Abstract #4545)

Igor Puzanov
• Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients. (Abstract #4546)
  
  *M. Dror Michaelson*

• Discussion

  *Christopher W. Ryan, MD*

---

**Session Title**: Head and Neck Cancer  
**Session Type**: Poster Discussion Session  
**Display Time**: 8:00 AM - 12:00 PM  
**Display Location**: S102  
**Discussion Time**: 12:00 PM - 1:00 PM  
**Discussion Location**: S100a

- Chair
  
  *Jean-Pascal H. Machiels, MD, PhD*

**Brd. 1**

• A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT). (Abstract #5511)
  
  *Anthony T. C. Chan*

**Brd. 2**

• Five years’ results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. (Abstract #5512)
  
  *Volker Budach*

**Brd. 3**

• Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (NCT01086826). (Abstract #5513)
  
  *Maria Grazia Ghi*

**Brd. 4**

• A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. (Abstract #5514)
  
  *Eric Jeffrey Sherman*

**Brd. 5**

• Expression of p16, ERCC,1 and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial. (Abstract #5515)
  
  *Melissa Austin*

**Brd. 6**

• Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial. (Abstract #5516^)
  
  *Jan Baptist Vermorken*

• Discussion

  *A. Dimitrios Colevas, MD*

**Brd. 7**

• Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. (Abstract #5517)
  
  *Tanguy Y. Seiwert*
• Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. (Abstract #5518)  
  *Douglas Wilmot Ball*

• Safety, molecular, and imaging responses to cetuximab administered in a window preoperative study in squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5519)  
  *Sandra Schmitz*

• Role of c-MET pathway in the outcome prediction of cetuximab-based therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Abstract #5520)  
  *Victoria Casado*

• Differential expression of EGFR, HER2, P16, and high-risk (hr) HPV status in oropharyngeal (Or) and oral cavity (OC) squamous cell carcinoma (SCC). (Abstract #5521)  
  *Anne Sudaka*

• Exploratory pharmacodynamics (PD) trial to investigate the mechanism of action of RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), compared with cetuximab (C) in neoadjuvant head and neck squamous cell carcinoma (HNSCC). (Abstract #5522)  
  *Stéphane Temam*

• Differences in biomarker expression in HNSCC according to p53 status. (Abstract #5523)  
  *Rebecca Anne Feldman-Moreno*

• New DNA methylation markers associated with oral cancer (OC) development (dvlpt). (Abstract #5524)  
  *Pierre Saintigny*

• Discussion  
  *David N. Hayes, MD, MPH*

• Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria. (Abstract #5525)  
  *A. Dimitrios Colevas*

• Effects of low-level laser therapy in the prevention and treatment of concurrent chemoradiotherapy induced oral mucositis: A triple-blind randomized controlled trial. (Abstract #5526)  
  *P.U. Prakash Saxena*

• ARIX: A randomized trial of acupuncture versus oral care sessions in patients with chronic radiation-induced xerostomia following treatment for head and neck cancer. (Abstract #5527)  
  *Richard Simcock*

• Discussion  
  *David M. Brizel, MD*
Br. 19
• A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract. (Abstract #5528)
  Joseph A Califano

Br. 20
• Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. (Abstract #5529)
  Carlos Rodrigo Acevedo-Gadea

Br. 21
• The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129. (Abstract #5530)
  Evan John Wuthrick

Br. 22
• Outcomes of HIV patients treated with chemo-radiotherapy (CRT) for squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5531)
  Waleed Fouad Mourad

Br. 23
• Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. (Abstract #5532)
  Megan Ann Baumgart

• Discussion
  Jean-Pascal H. Machiels, MD, PhD

Session Title: Lymphoma and Plasma Cell Disorders
Session Type: Poster Discussion Session
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E354a

• Chair
  Michael E. Williams, MD

Br. 1
• R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study. (Abstract #8021)
  Richard Delarue

Br. 2
• Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNL. (Abstract #8022)
  Gerhard Held

Br. 3
• A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). (Abstract #8023)
  Michinori Ogura

Br. 4
• Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNL. (Abstract #8024)
  Michael Pfuehandschuh

Br. 5
• Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNL). (Abstract #8025)
  Niels Murawska
• Discussion
  
  Andrew David Zelenetz, MD, PhD

Brd. 6
• Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial. (Abstract #8026)
  
  Remy Gressin

Brd. 7
• Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study. (Abstract #8027)
  
  Nancy Bartlett

Brd. 8
• Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study. (Abstract #8028)
  
  Patrick B. Johnston

Brd. 9
• A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). (Abstract #8029)
  
  Kiyoshi Ando

• Discussion
  
  Anas Younes, MD

Brd. 10
• Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST). (Abstract #8030)
  
  Ralf Ulrich Trappe

Brd. 11
• CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. (Abstract #8031)
  
  Agnieszka Korfel

Brd. 12
• Phase Ib trial of AVL-292, a covalent inhibitor of Bruton’s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). (Abstract #8032)
  
  Jennifer R. Brown

Brd. 13
• Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study. (Abstract #8033)
  
  Paul Gerard Guy Richardson

Brd. 14
• Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study. (Abstract #8034)
  
  Shaji Kumar

Brd. 15
• Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. (Abstract #8035)
  
  David Samuel DiCapua Siegel
Brd. 16
- Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma. (Abstract #8036)
  Adriana C. Rossi

Brd. 17
- Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM). (Abstract #8037)
  Robert M. Rifkin

Brd. 18
- Risk factors for development of second primary malignancies (SPM) after autologous stem cell transplant (ASCT) for multiple myeloma. (Abstract #8038)
  Amrita Y. Krishnan

Brd. 19
- Second cancer risk 40 years after cure for Hodgkin lymphoma. (Abstract #8039)
  Michael Schaapveld

- Discussion
  Philip L. McCarthy, MD

Brd. 20
- Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (AutoHCT) in multiple myeloma. (Abstract #8040)
  Koji Sasaki

Brd. 21
- Metronomic therapy for heavily pretreated relapsed/refractory multiple myeloma (RRMM). (Abstract #8041)
  Xenofon Papanikolaou

Brd. 22
- Detection of the MYD88 L265P mutation in Waldenström’s macroglobulinemia using a highly sensitive allele-specific PCR assay. (Abstract #8042)
  Lian Xu

Brd. 23
- Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. (Abstract #8043)
  Irene M. Ghobrial

- Discussion
  Sergio Giralt, MD

Session Title: Breast Cancer - HER2/ER
Session Type: General Poster Session
Time: 8:00 AM - 12:00 PM
Location: S Hall A2

Brd. 1A
- Statin use and the development of bone metastasis in breast cancer patients. (Abstract #536)
  Gentry T King

Brd. 1B
- ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy. (Abstract #537)
  Young Kwang Chae
• Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (Abstract #538)
  
  Judy-Anne W. Chapman

• BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. (Abstract #539)
  
  J. Thaddeus Beck

• BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (Abstract #540)
  
  Shinzaburo Noguchi

• Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. (Abstract #541)
  
  Cristina Pirvulescu

• Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines. (Abstract #542)
  
  Martin Filipits

• Interpathologists discrepancies in Ki67 assessment in the PACS01 trial: An independent prognosis factor. (Abstract #543)
  
  Frederique Madeleine Penault-Llorca

• A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. (Abstract #545)
  
  Bianchini Giampaolo

• A meta-analysis of receptor status discordance between primary breast cancer and metastases. (Abstract #546)
  
  Gaetano Aurilio

• Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. (Abstract #547)
  
  Joyce O'Shaughnessy

• Bisphosphonates in the adjuvant setting of breast cancer therapy: Effect on survival—A systematic review and meta-analysis. (Abstract #548)
  
  Liath Vidal

• A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers. (Abstract #549^)
  
  James Ashley Davidson

• CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen. (Abstract #550)
  
  Bavanthi Balakrishnar
Brd. 3B
• Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. (Abstract #551)
  Kathleen I. Pritchard
Brd. 3C
• Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial. (Abstract #552)
  Oleg Gluz
Brd. 3D
• Cost-effectiveness of zoledronic acid (ZOL) in postmenopausal women with early breast cancer receiving adjuvant letrozole. (Abstract #553)
  Mei Xue
Brd. 3E
• Chemotherapy-induced amenorrhea in premenopausal breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy within the SUCCESS study. (Abstract #554)
  Julia Katharina Neugebauer
Brd. 3F
• Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS). (Abstract #555)
  Kimberly Ridolfi
Brd. 3G
• Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. (Abstract #556)
  Nicolai Maass
Brd. 3H
• Predicting the Oncotype DX score: An inexpensive guesstimation. (Abstract #557)
  Catherine Pesce
Brd. 4A
• Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer. (Abstract #558)
  Bostjan Seruga
Brd. 4B
• Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. (Abstract #559)
  Martine J. Piccart-Gebhart
Brd. 4C
• The impact of the Oncotype Dx breast cancer assay in clinical practice: Systematic review and meta-analysis. (Abstract #560)
  Josh John Carlson
Brd. 4D
• Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study. (Abstract #561)
  Dennis Sgroi
Brd. 4E
• Association of the phosphorylation of the estrogen receptor at serine 118 and 167 with prognosis in postmenopausal breast cancer patients. (Abstract #562)
  Karin J. Beelen
• Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX). (Abstract #563)
  Wendy M. Ledesma

• Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts. (Abstract #564)
  Anthony D. Elias

• Prognostic factor Ki67 for breast cancer patients in each subgroup. (Abstract #565)
  Naoki Niikura

• Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts). (Abstract #566)
  Alejandro Navarro

• Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer. (Abstract #567)
  Pamela Klein

• Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France. (Abstract #568^)
  Joseph Gligorov

• Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC). (Abstract #569)
  Meghan Fitzgerald

• Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the United Kingdom, Germany, France, Spain, and Italy (EU-5): Results from a physician survey. (Abstract #570)
  Mitch DeKoven

• Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS). (Abstract #571)
  Kristina E. Bowen

• Synchronous bilateral breast cancer (SBBC): Concordance of receptor status between right and left breast. (Abstract #572)
  Palak Desai

• In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients. (Abstract #573)
  Maria Vassilakopoulou

• ERβ mRNA expression in ERα-negative and triple-negative breast cancers. (Abstract #574)
  Young Choi
Brd. 6B
• Fertility preservation options and the young breast cancer patient: A survey. (Abstract #575)
  Manuela Jacobsen Junqueira

Brd. 6C
• Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells. (Abstract #576)
  Elgene Lim

Brd. 6D
• Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients. (Abstract #577)
  Lisette Stork-Sloots

Brd. 6F
• Complementary role of Ki67 index and 70-gene signature (MammaPrint) high-risk patients in the St Gallen risk group with uncertain chemotherapy suggestion. (Abstract #579)
  Paolo Pronzato

Brd. 6G
• Breast cancer in Sub-Saharan Africa: 1,000 patients with primary breast cancer in Addis Ababa followed for up to 5 years. (Abstract #580)
  Eva Johanna Kantelhardt

Brd. 6H
• Assessment of method of breast cancer detection and Oncotype DX recurrence score. (Abstract #581)
  Ciara Marie Kelly

Brd. 7A
• Relationship between body mass index (BMI) at diagnosis of ER+ node negative breast cancer (BC) and Oncotype DX recurrence score. (Abstract #582)
  Caroline A. Lohrisch

Brd. 7B
• The role of Ki-67 in molecular breast cancer classification. (Abstract #583)
  George Stathopoulos

Brd. 7C
• Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy. (Abstract #584)
  Farideh Z. Bischoff

Brd. 7D
• Correlation, comparison, and combined analysis of Ki-67 and histological grade for early luminal breast cancer. (Abstract #585)
  Yoichi Naito

Brd. 7E
• Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting. (Abstract #586)
  Giorgio Mustacchi

Brd. 7F
• Endocrine therapy in early breast cancer: Encouraging observations in a nontrial setting. (Abstract #587)
  Susan Faye Dent
Brd. 7G
• A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01. (Abstract #588)
  Reiki Nishimura

Brd. 7H
• Multiple chemotherapy (CT) lines in metastatic breast cancer (MBC): Which survival benefit for women with hormone receptor (HR)-positive disease? (Abstract #589)
  Raffaella Palumbo

Brd. 8A
• Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in ER+ HER2- breast cancer. (Abstract #590)
  Hiroshi Yagata

Brd. 8B
• A short-term neoadjuvant pilot study comparing exemestane and letrozole in postmenopausal women with estrogen receptor-positive HER2-negative breast cancer. (Abstract #591)
  Daishu Miura

Brd. 8C
• ESR1 gene amplification and protein expression in 946 patients with resected breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) translational research study. (Abstract #592)
  George E. Pentheroudakis

Brd. 8D
• Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2- breast cancer. (Abstract #593)
  Pamela Landsman-Blumberg

Brd. 8E
• Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). (Abstract #594)
  Ricardo H. Alvarez

Brd. 8F
• Neoadjuvant chemotherapy versus neoadjuvant hormonal therapy in postmenopausal women with ER-positive, HER2/neu negative locally advanced breast cancer. (Abstract #595)
  Tadeu Frantz Ambros

Brd. 8G
• Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (Abstract #596)
  Ian Edward Smith

Brd. 8H
• Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. (Abstract #597^)
  José Baselga

Brd. 9A
• Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (Abstract #598^)
  Javier Cortes
• Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN). (Abstract #599)

  Ines Maria Vaz Duarte Luis

• Trastuzumab-related cardiotoxicity among older breast cancer patients. (Abstract #600)

  Mariana Chavez-Mac Gregor

• Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2 overexpressing breast carcinomas. (Abstract #601)

  Jean-Sebastien Frenel

• Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER). (Abstract #602)

  Maria Fernandez Abad

• Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases. (Abstract #603)

  Wojciech Biernat

• Lapatinib in HER2+ early breast cancer: Quality of life analysis. (Abstract #604)

  Frances Boyle

• A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). (Abstract #605)

  Carlos L. Arteaga

• A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). (Abstract #606)

  Mothaffar F. Rimawi

• Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer. (Abstract #607)

  Allan Lipton

• Correlation of quantitative p95HER2 and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant (NEO) trastuzumab-containing therapy. (Abstract #608)

  Jose Caetano Villasboas

• Incidence and risk of central nervous system (CNS) metastases as a site of first recurrence in patients (pts) with HER2-positive (HER2+) breast cancer treated with adjuvant trastuzumab (T). (Abstract #609)

  Erin Macrae Olson
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results. (Abstract #610)

Mary E. Cianfrocca

A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. (Abstract #611)

Rachel Catherine Jankowitz

Survival outcomes in HER2-positive invasive lobular breast carcinoma. (Abstract #612)

Carlos Hernando Barcenas

Estrogen receptor (ER), Ki-67, p27Kip1, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab. (Abstract #613)

Sasagu Kurozumi

Quantitative HER2 measurement and PI3K mutation profile in matched primary and metastatic breast cancer tissues. (Abstract #614)

Weidong Huang

Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC). (Abstract #615)

Giuseppe Gullo

Can MRI accurately identify which patients with operable breast cancer will have a pathologic complete response after neoadjuvant therapy? (Abstract #616)

Carolyn Nessim

Neuromedin U: A potential predictive biomarker for HER2-targeted drugs. (Abstract #617)

Sweta Rani

Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial. (Abstract #618)

John D. Hainsworth

Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab. (Abstract #619)

Davis Yuri Torrejon

Use of HER2 score correction for putative chromosome 17 (Chr-17) aneusomy to increase eligibility for anti-HER2 therapy. (Abstract #620)

Eugen C. Minca

Susceptibility of HER2+ breast cancer cells to poly (ADP-ribose) polymerase (PARP) inhibition independent of an inherent DNA repair defect. (Abstract #621)

Eddy Shih-Hsin Yang
Brd. 12A
- ADAM17 as a novel therapeutic target for HER2-positive breast cancer. (Abstract #622)
  
  Sumainizah Sukor

Brd. 12B
- HER2 assessment and Ki-67 labeling index in a cohort of male breast cases: The Ich Network on Cancer Research (INCaRe) experience. (Abstract #623)
  
  Giovanna Masci

Brd. 12C
- Phase I/II trial of primary chemotherapy with nonpegylated liposomal doxorubicin, paclitaxel, and lapatinib in patients with HER2-positive, early-stage breast cancer. (Abstract #624)
  
  Sherko Kuemmel

Brd. 12D
- An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial. (Abstract #625)
  
  Diane F Hale

Brd. 12E
- Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway. (Abstract #626)
  
  Pradip De

Brd. 12G
- Detection of trastuzumab (T) level in human serum using quartz crystal microbalance (QCM) piezo-immunosensors by immobilization of a HER2 mimotope-derived synthetic peptide and its potential application in breast cancer. (Abstract #628)
  
  Mohammad Muhsin Chisti

Brd. 12H
- Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy. (Abstract #629)
  
  Andrea Fontana

Brd. 13A
- Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials. (Abstract #630)
  
  Jenny Furlanetto

Brd. 13B
- Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer. (Abstract #631)
  
  Valentina Guarneri

Brd. 13C
- Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines. (Abstract #632)
  
  Alexandra Canonici

Brd. 13D
- Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX. (Abstract #633)
  
  Alex J. Eustace

Brd. 13E
- Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer. (Abstract #634)
  
  Caroline Diorio
• Effect of heterogeneity of HER2 expression on brain metastases of breast cancer. (Abstract #635)
  
  Mari Hosonaga

Brd. 13G
• Adjuvant treatment of early-stage HER2+ elderly breast cancer patients: A retrospective, multicenter French study. (Abstract #636)
  
  Philippe Barthelemy

Brd. 13H
• The effects of lapatinib and neratinib on HER2 protein levels in breast cancer cell lines. (Abstract #637)
  
  Denis Collins

Brd. 14A
• Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study. (Abstract #638)
  
  Muhammet Ali Kaplan

Brd. 14B
• Functional imaging of HER2-positive metastatic breast cancer using64Cu DOTA-trastuzumab positron emission tomography (PET). (Abstract #639)
  
  Joanne E. Mortimer

Brd. 14C
• Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites: Results from a large noninterventional study. (Abstract #640)
  
  Christian Jackisch

Brd. 14D
• Outcome of HER2-positive breast cancer patients (Pts) following metastatic relapse after adjuvant trastuzumab treatment since EMA regulatory approval. (Abstract #641)
  
  Jean-Philippe Spano

Brd. 14E
• Estrogen receptor in HER2-positive early breast cancer: Two different diseases? (Abstract #642)
  
  Eva Maria Ciruelos Gil

Brd. 14F
• Correlation of TOP2A expression in HER2-positive breast cancer with pathologic response and clinical outcomes in patients undergoing neoadjuvant treatment based on anthracycline. (Abstract #643)
  
  Elizabeth S. Santos

Brd. 14G
• Time to brain metastasis (TTBM) from initial diagnosis of distant metastasis in breast cancer: Prediction of TTBM according to breast cancer subtypes and treatment effect. (Abstract #644)
  
  Yeon Hee Park

Brd. 14H
• Relationship between changes in left ventricular ejection and use of angiotensin-converting enzyme inhibitors and/or betablockers during adjuvant trastuzumab chemotherapy in early breast cancer: Data from the real world. (Abstract #645)
  
  Francesco Giotta
• An open-label randomized, multicenter, phase II study of neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description. (Abstract #TPS646)

Alexandre Cochet

Brd. 15B

• LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. (Abstract #TPS647)

Heikki Joensuu

Brd. 15C

• BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC). (Abstract #TPS648)

Sara A. Hurvitz

Brd. 15D

• LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. (Abstract #TPS649)

Nadia Harbeck

Brd. 15E

• Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). (Abstract #TPS650)

Charles Swanton

Brd. 15F

• LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). (Abstract #TPS651)

Tamas Hickish

Brd. 15G

• A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. (Abstract #TPS652)

Ahmad Awada

Brd. 15H

• A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). (Abstract #TPS653)

Edith A. Perez

Brd. 16A

• Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). (Abstract #TPS654^)

Mothaffar F. Rimawi

Brd. 16B

• Docetaxel, carboplatin, trastuzumab, and bevacizumab (TCH+B) for early-stage HER2/neu(+) breast cancer and bone marrow micrometastases. (Abstract #TPS655)

Joseph Baar
LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. (Abstract #TPS656)

Carey K. Anders

A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. (Abstract #TPS657)

Melody A. Cobleigh

HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (Abstract #TPS658)

Nancy U. Lin

WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes. (Abstract #TPS659)

Toshimi Takano

The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer. (Abstract #TPS660)

Helena Margaret Earl

ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy. (Abstract #TPS661)

William John Gradishar

HIT: A multicenter phase I-II study of trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2+ metastatic breast cancer. (Abstract #TPS662)

Maya Gutierrez

A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. (Abstract #TPS663)

Pamela N. Munster

A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. (Abstract #TPS664)

Gayathri Nagaraj

OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study. (Abstract #TPS665)

Rob Stein

Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy. (Abstract #TPS666)

Joyce O'Shaughnessy
• ASTER 70s: Benefit of adjuvant chemotherapy for estrogen receptor-positive HER2-negative breast cancer in women over 70 according to genomic grade—A French GERICO/UCBG UNICANCER multicenter phase III trial. (Abstract #TPS667)
  
  Etienne Brain

• MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer. (Abstract #TPS668)
  
  Anthony D. Elias

• Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors. (Abstract #TPS669)
  
  Melinda Irwin

• Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial. (Abstract #TPS670)
  
  Paul Edward Goss

Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Session Type: General Poster Session

Time: 8:00 AM - 12:00 PM

Location: S Hall A2

• Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. (Abstract #1034)
  
  Yazan Migdady

• Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel. (Abstract #1035)
  
  Arvind Manohar Shinde

• A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484). (Abstract #1036)
  
  Daniel Rayson

• Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. (Abstract #1037)
  
  Sara A. Hurvitz

• Single institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC). (Abstract #1038)
  
  Anna Kaminsky

• Association between vitamin D deficiency and breast cancer histology: A retrospective database review. (Abstract #1039)
  
  Ranjana S. Bhargava

• Frequency of TLE3 overexpression in breast carcinoma subtypes including a large cohort of triple-negative patients. (Abstract #1040)
  
  Gargi D. Basu
• Epigenetic aspects of triple-negative in patients with breast cancer. (Abstract #1041)
  *Joaquina Martínez-Galan*

• Preclinical evaluation of PARP inhibition in breast cancer: Comparative effectiveness of olaparib and iniparib. (Abstract #1042)
  *Maura B. Cotter*

• Molecular characteristics and metastasis predictor genes of triple-negative breast cancer. (Abstract #1043)
  *Wen-Hung Kuo*

• Association of body mass index and outcome in advanced breast cancer. (Abstract #1044)
  *Claudia Andreetta*

• Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. (Abstract #1045)
  *Natalie Faye Sinclair*

• Patterns in circulating microRNA in black (B) versus white (W) patients with triple-negative (TN) breast cancer (BC). (Abstract #1046)
  *Iuliana Shapira*

• Molecular comparison of human triple-negative inflammatory breast cancer (TN-IBC) and human triple-negative noninflammatory breast cancer (TN-non-IBC). (Abstract #1047)
  *Hiroko Masuda*

• Racial differences in outcomes of triple-negative breast cancer. (Abstract #1048)
  *Jose Pacheco*

• A prognostic model for predicting breast cancer (BC)-related survival in operable triple-negative (TN) patients (pts). (Abstract #1049)
  *Elisabetta Munzone*

• Evaluation of a multiparametric system able to predict nonsentinel lymph node status in breast cancer patients with a micrometastatic sentinel node assessed by the one step nucleic acid amplification (OSNA) assay. (Abstract #1050)
  *Simonetta Buglioni*

• Impact of biomarkers in predictivity of the efficacy and toxicity of a combination of panitumumab plus FEC 100 followed by docetaxel in a phase II neoadjuvant trial for triple-negative breast cancer (TNBC) patients. (Abstract #1051)
  *Jean-Marc A. Nabholz*

• Effect of therapeutic targeting of the oncogene EMP2 in triple-negative breast cancer on tumor load. (Abstract #1052)
  *Madhuri Wadehra*
Clinical characteristics and chemotherapy options of triple-negative breast cancer: Role of classical CMF regimen. (Abstract #1053)

Min Hee Hur

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (Abstract #1054)

Takafumi Sangai

Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). (Abstract #1055)

Dilara McCauley

The role and significance of FoxM1 in invasive breast cancer. (Abstract #1056)

Cha Kyong Yom

Use of gene expression and alternative splicing signatures to discriminate breast cancer stem cells from fibroblasts. (Abstract #1057)

David T. Weaver

Next-generation sequencing mutational analysis of triple-negative breast cancer patients from matched FFPE and fresh frozen samples. (Abstract #1058)

Mark Landers

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data. (Abstract #1059)

Andreas Schneeweiss

Phase II study of a novel neoadjuvant chemotherapy (NAC) for breast cancer (BC). (Abstract #1060)

Miguel E. Albino

The first two lines of chemotherapy for anthracycline-naïve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines. (Abstract #1061)

Wei-Wu Chen

Current patterns of chemotherapy and supportive care for early-stage breast cancer (ESBC). (Abstract #1062)

Gary H. Lyman

Chemotherapy of methioninase-synchronized S/G2 phase-blocked cancer cells identified by cell cycle-specific fluorescent reporters. (Abstract #1063)

Shuya Yano

Low-dose, short-course sunitinib may normalize tumor vasculature and improve tumor blood flow to enhance chemotherapy efficacy in breast cancers. (Abstract #1064)

Soo-Chin Lee

Efficacy of low-dose capecitabine in metastatic breast cancer. (Abstract #1065)

Caitlin Bertelsen
Brd. 23A
- Early changes in angiogenesis and hypoxia following bevacizumab therapy in primary breast cancer. (Abstract #1066)
  Shaveta Mehta

Brd. 23B
- Accuracy of MRI, mammography (MG), and 2D and 3D ultrasound (2DUS/3DUS) in determining the pathologic tumor response after neoadjuvant chemotherapy (NACT) in breast cancer patients. (Abstract #1067)
  Markus Hahn

Brd. 23C
- Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer. (Abstract #1068)
  Wei Shen

Brd. 23D
- Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER2-negative metastatic breast cancer patients. (Abstract #1069)
  Tamer Refaat

Brd. 23E
- Phase I trial of ixabepilone and vorinostat in metastatic breast cancer. (Abstract #1070)
  Thehang H. Luu

Brd. 23F
- Outcomes of 47 patients with human immunodeficiency virus infection treated for breast cancer: A 20-year experience. (Abstract #1071)
  Roberto Enrique Ochoa

Brd. 23G
- Prognostic impact of weight change during chemotherapy. (Abstract #1072)
  Nikola S. Kasprowicz

Brd. 23H
- Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment. (Abstract #1073)
  Lucia Del Mastro

Brd. 24A
- Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis. (Abstract #1074)
  Isabel Chirivella

Brd. 24B
- Cancer stem cell markers in locally advanced breast cancer. (Abstract #1075)
  Daniel G. Tiezzi

Brd. 24C
- EEG for evaluation of "chemobrain." (Abstract #1076)
  Halle C. F. Moore

Brd. 24D
- Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study. (Abstract #1077)
  Iris Schrader
• Comparing the outcome between multifocal, multicentric, and bilateral breast cancer and the impact of guideline-adherent adjuvant treatment: A retrospective multicenter cohort study of 5,308 patients. (Abstract #1078)
  
  Lukas Schwentner

• Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study. (Abstract #1079)
  
  Yen-Shen Lu

• Baseline comprehensive geriatric assessment to predict for toxicity of single-agent chemotherapy in elderly metastatic breast cancer patients: Results from the OMEGA study of the Dutch Breast Cancer Trialists’ Group. (Abstract #1080)
  
  Marije Hamaker

• Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: Final survival analysis of the German ADEBAR phase III study. (Abstract #1081)
  
  Wolfgang Janni

• Participation in adjuvant clinical breast cancer trials: Is there a difference in survival compared to guideline adherent adjuvant treatment? A retrospective multicenter cohort study of 5,326 patients. (Abstract #1082)
  
  Achim Wöckel

• Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer (N1031, Alliance). (Abstract #1083)
  
  Kostandinos Sideras

• Reduction of ovarian reserve in young early breast cancer patients: First data of a prospective cohort trial. (Abstract #1084)
  
  Lea Sanders

• Methallotionein expression and outcome in patients with metastatic breast cancer (MBC). (Abstract #1085)
  
  Jorge Arturo Rios-Perez

• Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI). (Abstract #1086)
  
  John H. Barton

• BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy. (Abstract #1087)
  
  Katerina Bouchalova

• Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival. (Abstract #1088)
  
  Erin-Siobhain Ross Currin
• Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC). (Abstract #1089)

Terence Mukonje

• Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival? (Abstract #1090)

Markus Wallwiener

• Validation of NAD(P)H quinone oxidoreductase (NQO1) expression as a predictive factor for adjuvant chemotherapy benefit in patients with early breast cancer. (Abstract #1091)

Monica Arnedos

• Analysis of pretreatment nonpharmacologic, pharmacologic factors, and yoga intervention on CINV outcomes in breast cancer patients undergoing adjuvant chemotherapy. (Abstract #1093)

Malur R. Usharani

• The relative value of anti-Müllerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: Results from the OPTION trial. (Abstract #1094)

Robert C. F. Leonard

• Management of antiangiogenics’ renovascular safety in breast cancer subgroup and intermediate results of the MARS study. (Abstract #1095)

Catherine Daniel

• Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials. (Abstract #1096)

Frederik Marme

• Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate (Abstract #1097)

Fang LI

• A study of sperm-associated antigen 5 (SPAG5) in predicting response to anthracycline (ATC)/platinum chemotherapies (CT) in breast (BC) and ovarian cancers (OVC). (Abstract #1098)

Tarek M. A. Abdel-Fatah

• Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis. (Abstract #1099)

Cristiano Ferrario

• Receipt of locoregional therapy among young women with breast cancer. (Abstract #1100)

Rachel A. Freedman

• Patterns of regional node irradiation therapy following breast-conserving surgery: Report from the National Cancer Data Base 2003-2007. (Abstract #1101)

Ningqi Hou
• Primary tumor resection to improve survival and local disease control in stage IV inflammatory breast cancer. (Abstract #1102)
  Catherine Liebig Akay

• SPIO-enhanced MR imaging for axillary staging to avoid sentinel node biopsy in patients with breast cancer. (Abstract #1103)
  Kazuyoshi Motomura

• Breast cancer multifocality-multicentricity and survival outcomes. (Abstract #1104)
  Siobhan P. Lynch

• Is there a need for sentinel lymph node biopsy in microinvasive breast cancer? (Abstract #1105)
  Nimmi S. Kapoor

• Prognosis of early breast cancer patients treated with sentinel node biopsy: A prospective study from the Japanese society for sentinel node navigation surgery. (Abstract #1106)
  Shigeru Imoto

• Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071). (Abstract #1107)
  Huong T. Le-Petross

• Post-neoadjuvant chemotherapy sentinel node biopsy and axillary sampling for node negative (N0) axilla. (Abstract #1108)
  Vani Parmar

• Accuracy of breast MRI in predicting pathologic tumor size. (Abstract #1109)
  Kimberly Anne Caprio

• Magnetic resonance imaging (MRI) evaluation of pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC). (Abstract #1111)
  Lucia Gonzalez-Cortijo

• Comparison of long-term results of endoscopic video-assisted breast surgery (VABS) between transaxillary retromammary approach (TARM) and periareolar approach. (Abstract #1112)
  Koji Yamashita

• The impact of primary surgery on stage IV breast cancer. (Abstract #1113)
  Ella Harris

• Prognostic impact of local therapy of the primary tumor in metastatic breast cancer. (Abstract #1114)
  Isabelle Katrin Himsl

• Role of breast surgery in T1-T3 breast cancer patients with synchronous bone metastases. (Abstract #1115)
  Edoardo Botteri
• Postmastectomy radiotherapy for patients with one to three positive lymph nodes: Utilization and benefit. (Abstract #1116)
  Dezheng Huo

• Patient factors and satisfaction in the choice of contralateral prophylactic mastectomy. (Abstract #1117)
  Amanda Kathleen Arrington

• Predictors of recurrence in postmastectomy patients with one to three positive lymph nodes. (Abstract #1118)
  Tracy-Ann Moo

• Radiofrequency ablation (RFA) of breast cancer: A multicenter retrospective analysis. (Abstract #1119)
  Toshikazu Ito

• Feasibility of sentinel node biopsy in patients with locally advanced breast cancer after neoadjuvant therapy: A pilot study. (Abstract #1120)
  Ariadna Tibau Martorell

• Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? (Abstract #1121)
  Anees B. Chagpar

• Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. (Abstract #1122)
  Rachel Adams Greenup

• Long-term rates of breast cancer in a population of women with ductal carcinoma in situ treated by breast-conserving surgery. (Abstract #1123)
  Eileen Rakovitch

• Clinical findings and outcomes from MRI staging of breast cancers in women. (Abstract #1124)
  Akshara Raghavendra

• Overuse of sentinel lymph node biopsy with breast conserving surgery for clinical DCIS. (Abstract #1125)
  Natalie Beckman Jones

• Axillary lymph node status in breast cancer staging: What patient and tumor factors affect the accuracy of ultrasound-guided fine needle aspiration? (Abstract #1126)
  Celin Chacko

• Breast cancer surgery during pregnancy. (Abstract #1127)
  Rakesh Surapaneni

• Phase I/II trial of partial breast irradiation (PBI) with various concurrent chemotherapy regimens. (Abstract #1128)
  Lana Maria De Souza Lawrence
• 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) as early imaging biomarker of axillary sentinel lymph node (SLN) status in locally advanced node-positive breast cancer (NPBC) patients (pts) receiving neoadjuvant chemotherapy (NACT). (Abstract #1129)
  
  Yanina Dockx

• Evaluation of the stage IB designation of the 7th edition of the AJCC Staging System. (Abstract #1130)
  
  Nikolaos Andreas Dallas

• Prospective outcomes trial of immediate, implant breast reconstruction using acellular dermal matrix (POBRAD Trial): Pilot series results. (Abstract #1131)
  
  David Westbroek

• Breast cancer in older women. (Abstract #1132)
  
  David B. Pearlstone

• Scoring system for prediction of having three or more involved axillary nodes for breast cancer. (Abstract #1133)
  
  Soo Kyung Ahn

• Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer. (Abstract #TPS1134)
  
  Sara E. Barnato

• A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubincin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients. (Abstract #TPS1135)
  
  Peng Yuan

• ANZ1001 SORBET: Study of estrogen receptor beta and efficacy of tamoxifen, a single arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer. (Abstract #TPS1136)
  
  Kelly-Anne Phillips

• Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. (Abstract #TPS1137)
  
  Jessica N. Snider

• ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors. (Abstract #TPS1138)
  
  Jorge Arturo Rios-Perez

• Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients. (Abstract #TPS1139)
  
  Adriana Aguilar-Mahecha
• Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (Abstract #TPS1140)

  Edith A. Perez

• Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. (Abstract #TPS1141)

  Norio Kohno

• NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer. (Abstract #TPS1142)

  Louis Fehrenbacher

• IBL2001: Phase (ph) I/II study of a novel dose-dense (dd) schedule of indibulin for the treatment of metastatic breast cancer. (Abstract #TPS1143)

  Tiffany A. Traina

• ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer. (Abstract #TPS1144)

  Helena Margaret Earl

• A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC). (Abstract #TPS1145)

  Tiffany A. Traina

• DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC). (Abstract #TPS1146)

  Carsten Hagenbeck

• A multicenter prospective study of image-guided radiofrequency ablation for small breast carcinomas. (Abstract #TPS1147)

  Takayuki Kinoshita

• Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer. (Abstract #TPS1148)

  Fabrice Andre

---

**Session Title:** Patient and Survivor Care  
**Session Type:** General Poster Session  
**Time:** 8:00 AM - 12:00 PM  
**Location:** S Hall A2

• Difficult conversations with terminal patients: Palliative care and death at home. (Abstract #
Eduardo L. Morgenfeld
Brd. 38B
• In-hospital cancer care: Are we missing an opportunity for end of life care? (Abstract #9039)
  Gabrielle Betty Rocque

Brd. 38C
• Palliative cancer therapy during end of life at a regional cancer centre in Norway in 2005 and 2009. (Abstract #9040)
  Mari Aas Gynnild

Brd. 38D
• Effect of chemotherapy and psychosocial distress parameters on perceived cognitive disturbances in Asian breast cancer patients. (Abstract #9041)
  Yin Ting Cheung

Brd. 38E
• Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. (Abstract #9042)
  Andrea Pusic

Brd. 38F
• Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and nonautologous breast reconstruction. (Abstract #9043)
  Amie Scott

Brd. 38G
• Predictors of resilience in women treated for breast cancer: A prospective study. (Abstract #9044)
  Barbara Kaye Bennett

Brd. 38H
• Predictors of satisfaction with decision in patients with advanced cancer. (Abstract #9045)
  Felicitas Hitz

Brd. 39A
• Patient-related factors influencing time between first signs of breast cancer (BC) and appointment for medical visit (AMV): An international survey. (Abstract #9046)
  Jacek Jassem

Brd. 39B
• Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Abstract #9047)
  Amylou C. Dueck

Brd. 39D
• Patient-physician communication about code status preferences: A randomized controlled trial. (Abstract #9049)
  Wadih Rhondali

Brd. 39E
• Smoking habits of relatives of patients (pts) with cancer. (Abstract #9050)
  Mutlu Hayran

Brd. 39F
• Psychosocial correlates of sleep architecture in women with advanced breast cancer. (Abstract #9051)
  Arianna Aldridge Gerry
• Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: A randomized phase II study. (Abstract #9052)
   Gil Bar-Sela

• 3D index calculated from duration and severity of neutropenia and a degree of fever as prognostic factors predicting mortality of chemotherapy-induced febrile neutropenia in hematologic malignancies. (Abstract #9053)
   Ryosuke Shirasaki

• A positron emission tomography (PET) study to assess the degree of neurokinin-1 (NK1) receptor occupancy in the human brain after single doses of netupitant to healthy male subjects. (Abstract #9054)
   Giorgia Rossi

• Comparison of three different radiation fractionation schedules in the palliation of painful bone metastasis. (Abstract #9055)
   Monica Malik

• Pulmonary symptoms and their importance to patients with non-small cell lung cancer undergoing second- and third-line chemotherapy. (Abstract #9056)
   Susan Magasi

• Widespread use of complementary and alternative medicine (CAM) among non-Hodgkin lymphoma (NHL) survivors. (Abstract #9057)
   Alexis D. Leal

• Prospective survey study regarding the implementation of new communication skills curriculum for medical oncology trainees. (Abstract #9058)
   Nathan M. Shumway

• Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase III trial (SAKK 92/08). (Abstract #9059)
   Thomas Ruhstaller

• Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: results of open-label controlled phase I study with dose escalation in healthy volunteers. (Abstract #9060)
   Kirill D. Nikitin

• Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. (Abstract #9061)
   Steven M. Grunberg

• The effect of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo-controlled trial. (Abstract #9062)
   Egidio Del Fabbro
• Decision-making preferences of advanced cancer Hispanic patients from the United States and Latin America. (Abstract #9063)
  
  Henrique Afonseca Parsons

• The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. (Abstract #9064)
  
  Rudolph M. Navari

• Clinical needs of patients referred early to supportive and palliative care. (Abstract #9065)
  
  Jung Hye Kwon

• Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: A prospective cohort study. (Abstract #9066)
  
  Young Ho Yun

• Clostridium difficile-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin. (Abstract #9067)
  
  Oliver A. Cornely

• Interdisciplinary palliative care in metastatic non-small-cell lung cancer. (Abstract #9068)
  
  Marianna Koczywas

• Attrition rates, reasons, and predictive factors in supportive/palliative oncology clinical trials at a comprehensive cancer center. (Abstract #9069)
  
  Isabella Claudia Glitza

• Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome. (Abstract #9070)
  
  Hetty Prinsen

• Biomarkers of amenorrhea and ovarian function in breast cancer survivors. (Abstract #9071)
  
  Kathryn Jean Ruddy

• A randomized, double blind, placebo-controlled crossover trial of a sustained release methylphenidate in cancer-related fatigue. (Abstract #9072)
  
  Carmelita P. Escalante

• Genetic polymorphisms of SCNA9 as predictive markers of oxaliplatin-induced neuropathy. (Abstract #9073)
  
  Maria Sereno

• Psychological impact of exercise in women with breast cancer receiving adjuvant therapy: What is the optimal dose needed? (Abstract #9074)
  
  Marion Carayol

• Pilot study of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. (Abstract #9075)
  
  Deirdre R. Pachman
• Paucity of core palliative care elements available to children with cancer at end-of-life: Perspectives of bereaved parents and clinicians. (Abstract #9076)
  
  Alisha Kassam

• Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy. (Abstract #9077)
  
  Luis Enrique Fein

• Effect of aprepitant on adherence to high-dose cisplatin-based chemotherapy. (Abstract #9078)
  
  Serge Makarenko

• Development of a geriatric vulnerability score (GVS) in elderly advanced ovarian cancer (AOC) patients (pts) treated in first line: A prospective GINECO trial. (Abstract #9079)
  
  Gilles Freyer

• Correlations between depression according DSM-IV-TR (DSM) criteria, three validated scales, oncologist assessment, and clinical psychiatric interview in elderly advanced ovarian cancer (AOC) patients (pts): A GINECO study. (Abstract #9080)
  
  Mariène Filbet

• Inflammatory markers and symptom burden in patients with multiple myeloma undergoing autologous stem cell transplantation. (Abstract #9081)
  
  Loretta A. Williams

• Baseline subclinical sensory deficits and the development of pain and numbness in patients with multiple myeloma (MM) being treated with chemotherapy. (Abstract #9082)
  
  Elisabeth G. Vichaya

• Longitudinal relationship between inflammatory markers and patient-reported symptom severity during induction therapy for multiple myeloma. (Abstract #9083)
  
  Mary H Sailors

• Randomized trial of a physical activity intervention in patients with metastatic breast cancer. (Abstract #9084)
  
  Jennifer A. Ligibel

• A randomized trial to determine if vitamin B6 can prevent hand and foot syndrome in cancer patients treated with capecitabine chemotherapy. (Abstract #9085)
  
  Tareq Braik

• In-hospital and long-term outcomes in patients with malignancy undergoing percutaneous endoscopic gastrostomy (PEG). (Abstract #9086)
  
  Emily Zhi-Yun Keung

• Usefulness of medical oncologists’ estimates of survival time in people with advanced cancer. (Abstract #9087)
  
  Belinda E. Kiely
• Risk of rash with nilotinib: A systematic review of the literature and meta-analysis. (Abstract # 9088)
  Aaron Mark Drucker

• The chemotherapy-induced peripheral neuropathy (CIPN) outcome measure standardization (CI-PeriNomS) study: From consensus to validity and reliability in CIPN assessment. (Abstract # 9089)
  Guido Cavaletti

• Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. (Abstract # 9090)
  Andreas Argyriou

• Gender difference in vulnerability and geriatric syndromes among elderly cancer survivors. (Abstract #9091)
  Lin Fan

• Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis. (Abstract #9092)
  Emily Christine Case

• Feasibility of screening hospitalized cancer patients for palliative care. (Abstract #9094)
  Paul A. Glare

• Predicting length of survival for adult, outpatient oncology patients using clinic visit data. (Abstract #9095)
  Laura E. Brown

• Symptoms (Sx) in English (E) and Spanish (S) speaking children with cancer. (Abstract #9096)
  Donna S. Zhukovsky

• Vitamin D3 supplementation to improve fatigue in patients with advanced cancer. (Abstract # 9097)
  Dragan Trivanovic

• Medical oncologist’s commitment in the end of life (EoL) care of cancer patients: The caregiver’s perspective. (Abstract #9098)
  Romeo Bascioni

• Defining mild, moderate, and severe fatigue in cancer patients and survivors: E2Z02, a trial of the Eastern Cooperative Oncology Group. (Abstract #9099)
  Xin Shelley Wang

• Sexual functioning in young women with breast cancer. (Abstract #9100)
  Shoshana Rosenberg
• Early outpatient palliative care in patients with metastatic NSCLC: A qualitative study. (Abstract #9101)  
  Jaclyn Yoong

• Clinical trial participation as part of end-of-life (EOL) cancer care: Associations with medical care near death and bereaved caregivers’ mental health. (Abstract #9102)  
  Andrea Catherine Phelps

• Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). (Abstract #9103)  
  Ting Bao

• Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer. (Abstract #9104)  
  Shari Damast

• A randomized trial of a cardiopulmonary resuscitation (CPR) video (V) in advance care planning (ACP) for progressive hepatopancreaticobiliary cancer patients. (Abstract #9105)  
  Andrew S. Epstein

• Understanding the symptom experience of breast cancer outpatients: The validity and utility of the M.D. Anderson Symptom Inventory (MDASI). (Abstract #9106)  
  Tito R. Mendoza

• A randomized trial evaluating the integration of online questionnaires into follow-up (FU) care for early-stage breast cancer (ESBC). (Abstract #9107)  
  Alyse Wheelock

• Comparing three validated methods of patient self-reported fatigue in a prospective randomized clinical trial. (Abstract #9108)  
  Katherine Sams

• Anemia and functional disability in older adults with cancer. (Abstract #9109)  
  Cynthia Owusu

• Efficacy and safety of half-dose pegfilgrastim in cancer patients receiving cytotoxic chemotherapy. (Abstract #9110)  
  Ryan C. Ramaekers

• Continued suppression of bone turnover following a single dose of zoledronic acid: Time to rethink dosing intervals in the management of bone metastases? (Abstract #9111)  
  Christine E. Simmons

• Determinants of fatigue improvement in outpatient oncology according to baseline categories of fatigue severity. (Abstract #9112)  
  Michael Fisch
• Pain, sleep disturbance, and fatigue symptom cluster in patients suffering from chronic chemotherapy-induced neuropathic pain (CINP). (Abstract #9113)

  Jennifer S. Gewandter

• Treatment and mortality rates of older cancer patients with a body mass index

  Friedemann Honecker

• The effect of a supervised exercise program on arm girth measurements in breast cancer survivors. (Abstract #9115)

  Laura M. Leach

• Spiritual care provided by oncology physicians and nurses to advanced cancer patients. (Abstract #9116)

  Zachary Epstein-Peterson

• Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study. (Abstract #9117)

  Eric S. Winer

• Disease-driven symptoms and response to chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC). (Abstract #9118)

  Desiree Jones

• Evaluation of a non-peptidic mimic of host defense proteins, PMX30063, in an animal model of oral mucositis. (Abstract #9119)

  Richard W Scott

• Final results of a large collaborative, hospital-based, quality improvement study aimed at the implementation of interventions for the psychosocial care of adult cancer patients (HUCARE project). (Abstract #9120)

  Rodolfo Passalacqua

• Clinical ethics consultation in oncology. (Abstract #9121)

  Andrew G Shuman

• A prospective longitudinal study of cancer-related fatigue in patients undergoing breast-conserving surgery and radiation with or without chemotherapy for breast cancer. (Abstract # 9122)

  Mylin Ann Torres

• The relationship among age, anxiety, and depression in older adults with cancer. (Abstract # 9123)

  Talia Weiss

• A national survey of support and information needs of Australian women living with advanced breast cancer. (Abstract #9124)

  Linda R. Mileshkin
• Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. (Abstract #9125)
  Constantin D. Volovat

• Using scenarios to explain survival time: Attitudes of people with a cancer experience. (Abstract #9126)
  Martin R. Stockler

• A prospective study of family conferences (FCs) in a palliative care unit (PCU) at a comprehensive cancer center. (Abstract #9127)
  Rony Dev

• Caring for people at the end of life: How do cancer caregivers differ from other caregivers? (Abstract #9128)
  Afaf Girgis

• Polymorphisms in genes OPRM1, beta-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy. (Abstract #9129)
  Sara Cros

• Cognitive symptoms in non-Hodgkin lymphoma survivors: Prevalence and discussion with doctors. (Abstract #9130)
  Neeraj K Arora

• Prevalence of cancer-related fatigue in a population-based sample of colorectal, breast, and prostate cancer survivors. (Abstract #9131)
  Jennifer M Jones

• Addressing spirituality within the care of patients at the end of life: Perspectives of advanced cancer patients, oncologists, and oncology nurses. (Abstract #9132)
  Andrea C. Phelps

• Palonosetron (PALO) plus 1-day versus 3-day dexamethasone (DEX) with or without aprepitant against delayed nausea (DN): Pooled analysis for 554 women receiving highly emetogenic chemotherapy (HEC). (Abstract #9133)
  Luigi Celio

• Longitudinal study of hope, meaning/peace (M/P), and quality of life (QOL) in patients (pts) with ovarian cancer (OC). (Abstract #9134)
  Lois M. Ramondetta

• Prospective cohort study of chemotherapy-associated toxicity and supportive care in oncology practice. (Abstract #9135)
  Eva Culakova

• Associations between receipt of a treatment summary, emotional concerns, and patterns of care among post-treatment cancer survivors. (Abstract #9136)
  Ruth Rechis
Br. 50C
• Outpatient chemotherapy supportive care: Trial of an IT-integrated, NP-delivered system for unrelieved symptoms. (Abstract #9137)
  Kathi Mooney

Br. 50D
• Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling. (Abstract #9138)
  Julie Lemieux

Br. 50E
• Advance care planning (ACP) among hematopoietic cell transplant (HCT) patients and bereaved caregivers. (Abstract #9139)
  Elizabeth T Loggers

Br. 50F
• Validation of the chemotherapy-induced neuropathy assessment scale. (Abstract #9140)
  Sheeba K. Thomas

Br. 50G
• Physical and functional well-being in women with breast cancer taking gabapentin for hot flashes. (Abstract #9141)
  Kavita Dayal Chandwani

Br. 50H
• YOCAS yoga, fatigue, memory difficulty, and quality of life: Results from a URCC CCOP randomized, controlled clinical trial among 358 cancer survivors. (Abstract #9142)
  Michelle Christine Janelins

Br. 51A
• Changes in the use of erythropoetin-stimulating agents (ESAs) in cancer patients: Before and after FDA safety advisories. (Abstract #9143)
  Dana Stafkey-Mailey

Br. 51B
• Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer. (Abstract #9144)
  Sandra A. Mitchell

Br. 51C
• Health behaviors among testicular cancer survivors. (Abstract #9145)
  Steven C Palmer

Br. 51D
• Lifetime traumas and their influence on advanced cancer patients’ illness understanding and likelihood of end-of-life discussions. (Abstract #9146)
  Elizabeth L Kacel

Br. 51E
• Using cancer patient stories to “power” communication modules. (Abstract #TPS9147)
  Forrest Lang

Br. 51F
• Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. (Abstract #TPS9148)
  Liliana Moyers-Ruiz

Br. 51G
• CATCH: A randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. (Abstract #TPS9149^)
  Agnes Y. Lee
• Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517. (Abstract #TPS9150)

  Michael J. Seider

Brd. 52A

• Do we need to perform pulmonary function tests in non-small cell lung cancer patients never diagnosed as COPD?. (Abstract #TPS9151)

  Narongwit Nakwan

Brd. 52B

• Radioprotection study of topical norepinephrine in postsurgical breast cancer patients. (Abstract #TPS9152)

  James F. Cleary

Brd. 52C

• A multi-site, fixed dose, parallel arm, double-blind, placebo controlled, block randomised trial of the addition of infusional octreotide or placebo to regular ranitidine and dexamethasone for the evaluation of vomiting associated with bowel obstruction at the end of life. (Abstract #TPS9153)

  David C Currow

Brd. 52D

• The European InCASA telecare-telehealth electronic platform (ICT-FP7) for the daily assessment of symptoms, weight, and activity in cancer patients on chronotherapy at home. (Abstract #TPS9154)

  Francis Levi

Brd. 52E

• Assessing clinical appropriateness on a population basis within a regional cancer network. (Abstract #TPS9155)

  Paolo Giovanni Casali

**Session Title:** Management of Brain Metastases in Women with Breast Cancer - Ticketed Session

**Session Type:** Meet the Professor Session

**Time:** 9:30 AM - 10:45 AM

**Location:** E451a

• Discussion of Novel Systemic Approaches to and New Areas of Research in Brain Metastases

  Nancy U. Lin, MD

• Discussion of Radiation Oncology Management of Central Nervous System Metastatic Disease with Focus on Respective Roles of Whole-Brain Radiotherapy Stereotactic Radiosurgery

  Naren Ramakrishna, MD, PhD

**Session Title:** Opening Session with the Conquer Cancer Foundation Donor Recognition Awards, Fellows of the American Society of Clinical Oncology, ACS CEO’s Address, Presidential Address, ASCO Humanitarian Award, and the David A. Karnofsky Memorial Award and Lecture

**Session Type:** Special Session

**Time:** 9:30 AM - 12:00 PM

**Location:** N Hall B1

• Humanitarian Award Presentation

  Edith P. Mitchell, MD

• Progress in Chronic Lymphocytic Leukemia (CLL): A Tribute to Dr. David A. Karnofsky

  Kanti Roop Rai, MD

**Session Title:** Controversies in Prostate Cancer: PSA Screening, Chemoprevention, and Treatment of Early Disease

**Session Type:** Education Session

**Time:** 1:15 PM - 2:30 PM
Location: S404
• PSA Screening for Prostate Cancer
  Barnett S. Kramer, MD, MPH (Chair)
• Chemoprevention of Prostate Cancer
  Gerald L. Andriole, MD
• Management of Screen-Detected and Early-Stage Prostate Cancer
  Timothy J. Wilt, MD, MPH

Session Title: Avoiding Overdiagnosis and Overtreatment of Common Cancers
Session Type: Education Session
  Time: 1:15 PM - 2:30 PM
Location: S100a
• Overdiagnosis and Overtreatment in Oncology: An Overview
  Ruth D Etzioni, PhD
• Prostate Cancer: Overdiagnosis and Treatment
  Ian Murchie Thompson, MD (Chair)
• Ductal Carcinoma of the Breast: Avoiding Overdiagnosis and Treatment
  Laura Esserman, MD, MBA

Session Title: Controversies in Myeloma: Induction, Transplant, and Maintenance
Session Type: Education Session
  Time: 1:15 PM - 2:30 PM
Location: E354b
• Upfront Therapy for Myeloma: Tailoring Therapy across the Disease Spectrum
  S. Vincent Rajkumar, MD
• Transplantation for Multiple Myeloma Controversies: Who, How, and When
  Amrita Y. Krishnan, MD (Chair)
• Maintenance Therapy for Myeloma: How Much, How Long, and at What Cost?
  Michel Attal, MD

Session Title: Evolving Paradigms in the Management of Unresectable Pancreatic Cancer
Session Type: Education Session
  Time: 1:15 PM - 2:30 PM
Location: E Hall D2
• Making Sense of the New Options: FOLFIRINOX, Gemcitabine, and Other Systemic Therapies for Advanced Pancreatic Cancer
  Hedy Lee Kindler, MD (Chair)
• A Matter of Timing: Is There a Role for Radiation in Locally Advanced Pancreatic Cancer, and If So, When?
  Theodore S. Hong, MD
• A Myriad of Symptoms: New Approaches to Optimizing Palliative Care of Patients with Advanced Pancreatic Cancer
  Lauren Allison Wiebe, MD

Session Title: International Variation in Understanding Oncologists' Professional Duties toward Patients, Families, and Themselves
Session Type: Education Session
  Time: 1:15 PM - 2:30 PM
Location: E353
• Are Oncologists Responsible Only to Patients or Also to Their Families: An International Perspective
  Antonella Surbone, MD, PhD
• Conflicts Near the End of Life: Physician's Duty towards Patients and Families  
  Simon Wein, MD
• Relational, Spiritual, and Different Cultural Approaches to Oncologists' Duties toward Themselves  
  Amy Pickar Abernethy, MD (Chair)

---

**Session Title:** Thymoma and Thymic Carcinoma: Update on Management  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E Hall D1

• Management of Thymic Carcinoma  
  Gregory J. Riely, MD, PhD (Chair)
• Medical Oncology Therapy for Thymoma  
  Nicolas Girard, MD, MSc
• The Creation of ITMIG and the Model for Improvements in “Rare” Malignancies  
  Frank C. Detterbeck, MD

---

**Session Title:** Upfront Treatment of Ovarian Cancer: International Consensus and Variation  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E Arie Crown Theater

• Intraperitoneal Treatment in Ovarian Cancer: The Gynecologic Oncology Group Perspective in 2012  
  Deborah Kay Armstrong, MD
• Other Strategies in Upfront Treatment of Ovarian Cancer: Dose-Dense and Neoadjuvant Chemotherapy  
  Keiichi Fujiwara, MD, PhD
• Biologics in the Upfront Treatment in Ovarian Cancer: Focus on Bevacizumab and PARP Inhibitors  
  Gordon J. S. Rustin, MD, MBBS (Chair)

---

**Session Title:** When Cancer Becomes Personal: The Physician’s View of Patient Care  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E354a

• Introduction  
  Teresa Gilewski, MD (Chair)
• Going Public in the New York Times: Real-Time Thoughts about My Wife's Cancer  
  Peter Bach, MD
• Life on the Other Side of the Stethoscope  
  Martin N. Raber, MD
• The Physician as the Son and Friend: What I Learned about the Human Side of Medicine  
  George W. Sledge, MD

---

**Session Title:** Hormone Replacement Therapy: Weighing the Evidence - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E451a

• Menopausal Hormone Therapy and Common Cancers  
  Rowan T. Chlebowski, MD, PhD

---

**Session Title:** Toxicity from VEGF and mTOR-Targeted Agents in Renal Cell Carcinoma - Ticketed Session  
**Session Type:** Clinical Problems in Oncology Session
**Session Title:** Antiangiogenic Therapy in Brain Tumors: How Can We Resist?
**Session Type:** Clinical Science Symposium
**Time:** 1:15 PM - 2:45 PM
**Location:** S100bc

- **Chair**
  - Joon H. Uhm, MD
- **Discussion**
  - David A. Reardon, MD

- Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma. (Abstract #2009)
  - Elizabeth Robins Gerstner

- Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma. (Abstract #2010)
  - Christine Lu-Emerson

- Modulation of antiangiogenic resistance: Targeting the JAK/STAT3 pathway in glioblastoma. (Abstract #2011)
  - John Frederick De Groot

- Effects of cediranib (VEGF-signaling inhibitor) on edema in newly diagnosed glioblastoma patients during initial chemoradiation. (Abstract #2012)
  - Pavlina Polaskova

- Discussion
  - Tom Mikkelsen, MD

---

**Session Title:** HER2 or ER-Positive Breast Cancer: Exploiting Dysfunction in the PI3K Pathway
**Session Type:** Clinical Science Symposium
**Time:** 1:15 PM - 2:45 PM
**Location:** N Hall B1

- **Co-Chair**
  - Sumanta Kumar Pal, MD
- **Co-Chair**
  - Gunter Von Minckwitz, MD, PhD

- Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. (Abstract #507)
  - Sherene Loi

- A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. (Abstract #508)
  - Ian E. Krop

- Discussion
  - Carlos L. Arteaga, MD

- PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). (Abstract #509)
  - Mafalda Oliveira
• SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). (Abstract #510)
  Ingrid A. Mayer

• Discussion
  Stephen R. D. Johnston, MA, MD, PhD

Session Title: Immune Checkpoint Strategies
Session Type: Clinical Science Symposium
Time: 1:15 PM - 2:45 PM
Location: S406

• Chair
  Padmanee Sharma, MD, PhD

• Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (Abstract #CRA2509)
  Suzanne Louise Topalian

  Scott S. Tykodi

• Costimulatory effect of agonistic 4-1BB antibody on proliferation and effector phenotype of tumor-infiltrating lymphocytes in melanoma. (Abstract #2511)
  Amod Sarnaik

• Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. (Abstract #2512)
  Amita Patnaik

• Discussion
  James Patrick Allison, PhD

Session Title: Pediatric Oncology I
Session Type: Oral Abstract Session
Time: 1:15 PM - 4:15 PM
Location: S504

• Co-Chair
  Elizabeth A. Raetz, MD

• Co-Chair
  Jennifer Lynn McNeer, MD

• Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. (Abstract #9500)
  Yael P. Mosse

• Discussion
  Thomas G. Gross, MD, PhD

• Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Children’s Oncology Group. (Abstract #9501)
  J. Kimble Frazer

• Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial. (Abstract #9502)
  Monika Metzger

• Discussion
  Stephen E. Sallan, MD
• The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). (Abstract #9503)
  
  Lisa M. Kopp

• Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). (Abstract #9504)
  
  Barbara Asselin

• Efficacy of the Children’s Oncology Group (COG) long-term follow-up (LTFU) guidelines in reducing risk of congestive heart failure (CHF) in childhood cancer survivors (CCS). (Abstract #9505)
  
  F. Lennie Wong

• In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). (Abstract #9506)
  
  Sarah Kathleen Tasian

• Relapse-specific mutations in cytosolic 5’-nucleotidase II in childhood acute lymphoblastic leukemia. (Abstract #9507)
  
  Julia Meyer

• Discussion
  
  Robert John Arceci, MD, PhD

• Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group study AALL0232. (Abstract #CRA9508)
  
  Eric Larsen

---

**Session Title**: Breast Cancer - HER2/ER  
**Session Type**: Poster Discussion Session  
**Display Time**: 1:15 PM - 5:15 PM  
**Display Location**: E450a  
**Discussion Time**: 4:45 PM - 5:45 PM  
**Discussion Location**: E Hall D2

• Chair
  
  Stephen R. D. Johnston, MA, MD, PhD

Brd. 1  
• Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. (Abstract #511)
  
  Robert Edward Coleman

Brd. 2  
• Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). (Abstract #512)
  
  Michael Gnant

Brd. 3  
• Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. (Abstract #513)
  
  Walter Gregory

Brd. 4  
• Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial. (Abstract #514)
  
  Georg Pfeiler

• Discussion
  
  Catherine H. Van Poznak, MD
• Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. (Abstract #515)
  
  William Fraser Symmans

• Mammastrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study. (Abstract #516)
  
  John M. S. Bartlett

• Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. (Abstract #517)
  
  Jason Christiansen

• Gene methylation in random FNA samples as biomarkers for breast cancer. (Abstract #518)
  
  Vered Stearns

• Dual effects of metformin on breast cancer proliferation in a randomized trial. (Abstract #519)
  
  Andrea De Censi

• Reduction in Ki-67 in benign breast tissue of high-risk premenopausal women with the SERM acolbifene. (Abstract #520)
  
  Carol J. Fabian

• Aspirin use and mortality in women with stage I-II breast cancer: A population-based study. (Abstract #521)
  
  Thomas Ian Barron

• Discussion
  
  Mitchell Dowsett, PhD

• Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. (Abstract #522)
  
  Bruno Valentin Sinn

• Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. (Abstract #523)
  
  Jens Bodo Huober

• Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. (Abstract #524)
  
  Pedro Emanuel Rubini Liedke

• Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy. (Abstract #525)
  
  Norah Lynn Henry

• Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen. (Abstract #526)
  
  Vincent O. Dezentje
• Discussion
  
  **Bryan P. Schneider, MD**

Brd. 17
- Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. (Abstract #527)
  
  **Rashmi Krishna Murthy**

Brd. 18
- Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. (Abstract #528)
  
  **Shanu Modi**

Brd. 19
- Phase Ib study of open-label AMG 386 plus paclitaxel (P) and trastuzumab (T) or capecitabine (C) and lapatinib (L) in patients (pts) with HER2+ locally recurrent or metastatic breast cancer (MBC). (Abstract #529)
  
  **Hans Wildiers**

Brd. 20
- Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. (Abstract #530)
  
  **Anthony Kong**

Brd. 21
- A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). (Abstract #531)
  
  **Massimo Cristofanilli**

Brd. 22
- Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. (Abstract #532)
  
  **Chau T. Dang**

Brd. 23
- Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. (Abstract #533^)
  
  **Michael Ewer**

Brd. 24
- A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer. (Abstract #534)
  
  **Gini F. Fleming**

Brd. 25
- Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). (Abstract #535)
  
  **Eric P. Winer**

• Discussion
  
  **Anne F. Schott, MD**

---

**Session Title:** Developmental Therapeutics - Experimental Therapeutics  
**Session Type:** Poster Discussion Session  
**Display Time:** 1:15 PM - 5:15 PM  
**Display Location:** S405  
**Discussion Time:** 4:45 PM - 5:45 PM  
**Discussion Location:** S406
Co-Chair  
  Jin Li, MD

Co-Chair  
  E. Gabriela Chiorean, MD

Brd. 1  
- First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors. (Abstract #3009)  
  Michael Anthony Carducci

Brd. 2  
- Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results. (Abstract #3010)  
  Peter Lee

Brd. 3  
- A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. (Abstract #3011)  
  Sudeep Gupta

Brd. 4  
- A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule. (Abstract #3012)  
  Rastislav Bahleda

Brd. 5  
- A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor. (Abstract #3013)  
  Desiree Hao

Discussion  
  Gary K. Schwartz, MD

Brd. 6  
- Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials. (Abstract #3014)  
  Rodrigo Dienstmann

Brd. 7  
- Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity. (Abstract #3015)  
  Andrew Eugene Hendifar

Brd. 8  
- A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors. (Abstract #3016)  
  Luis A. Diaz

Brd. 9  
- Phase I study of oral rigosertib in patients with advanced solid tumors. (Abstract #3017)  
  Daniel W. Bowles

Brd. 10  
- Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. (Abstract #3018^)  
  Herlinde Dumez

Discussion  
  Kyriakos P. Papadopoulos, MD
• Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. (Abstract #3019)

  Michael T. Lotze

Brd. 12
• A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (Abstract #3020)

  Shabina Roohi Ahmed

Brd. 13
• A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors. (Abstract #3021)

  Cristina Saura

Brd. 14
• A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH513279, in patients with advanced solid tumors. (Abstract #3022)

  Aurelius Gabriel Omlin

Brd. 15
• A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors. (Abstract #3023)

  Carlos Becerra

Brd. 16
• PX-866 and docetaxel in patients with advanced solid tumors. (Abstract #3024)

  Antonio Jimeno

• Discussion

  Timothy Anthony Yap, BSc, MBBS, MRCP

Brd. 17
• A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors. (Abstract #3025)

  Anthony W. Tolcher

Brd. 18
• A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. (Abstract #3026)

  Nicolas Isambert

Brd. 19
• Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors. (Abstract #3027)

  Irene Brana

Brd. 20
• First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. (Abstract #3028)

  Daruka Mahadevan
Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. (Abstract #3029)

Gerald J. Fetterly

Discussion

Smita S. Krishnamurthi, MD

Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors. (Abstract #3030)

Gennaro Daniele

Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors. (Abstract #3031)

James H. Doroshow

Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib. (Abstract #3032)

Lee S. Rosen

NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent. (Abstract #3033)

Dana Shelton Thompson

Session Title: Melanoma/Skin Cancers
Session Type: Poster Discussion Session
Display Time: 1:15 PM - 5:15 PM
Display Location: E450b
Discussion Time: 4:45 PM - 5:45 PM
Discussion Location: E353

Co-Chair

Patrick Alexander Ott, MD, PhD

Co-Chair

Paul Lorigan, MD

Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study. (Abstract #8512)

Luc Thomas

Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (Abstract #8513)

Anna Maria Di Giacomo

Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. (Abstract #8514)

Sapna Pradyuman Patel

Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy. (Abstract #8515)

James J. Harding
• Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay. (Abstract #8516)
  
  Ryan J. Sullivan

• An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. (Abstract #8517)
  
  James M. G. Larkin

• Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (Abstract #8518)
  
  Georgina V. Long

• Discussion
  
  Mario Sznol, MD

• Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. (Abstract #8519)
  
  Julie Ann Means-Powell

• Clinical significance of genomic alterations of the CDK4 pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma. (Abstract #8520)
  
  Grant A. McArthur

• SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. (Abstract #8521)
  
  Christopher D. Lao

• A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). (Abstract #8522)
  
  Kevin Kalinsky

• A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM). (Abstract #8523)
  
  Paul D. Nathan

• A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: Interim analysis. (Abstract #8524)
  
  John P. Fruehauf

• Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933. (Abstract #8525)
  
  Kim Allyson Margolin

• Discussion
  
  Keith T. Flaherty, MD

• Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. (Abstract #8526)
  
  Friedegund Elke Meier
• CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. (Abstract #8527)

  Wolfram E. Samlowski

• Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival. (Abstract #8528)

  Michal Tadeusz Krauze

• The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. (Abstract #8529)

  Michele Maio

• Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies. (Abstract #8530)

  Craig L. Slingluff

• Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). (Abstract #8531)

  Michael S. Gordon

• Discussion

  Kim Allyson Margolin, MD

• Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. (Abstract #8532)

  Serge Leyvraz

• Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring. (Abstract #8533)

  Ahmad A. Tarhini

• Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases. (Abstract #8534)

  Donald L. Morton

• Sensitivity rate of ultrasound (US)-guided fine-needle aspiration cytology (FNAC) using the Berlin morphology criteria for lymph node metastases to reduce the need for surgical sentinel node (SN) staging in melanoma. (Abstract #8535)

  Christiane A. Voit

• Impact of comorbidities on overall survival of high-risk and advanced melanoma. (Abstract #8536)

  Prashanth Peddi

• Discussion

  Michael S. Sabel, MD

---

**Session Title:** Sarcoma  
**Session Type:** Poster Discussion Session  
**Display Time:** 1:15 PM - 5:15 PM
PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. (Abstract #10009)

Winette T.A. Van Der Graaf

Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results. (Abstract #10010)

Jean-Yves Blay

Phase I study of neoadjuvant chemoradiation (CRT) plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS). (Abstract #10011^)

Janelle Marie Meyer

18f-FDG-PET imaging as an early survival predictor in patients with high-grade soft tissue sarcomas undergoing neoadjuvant therapy. (Abstract #10012)

Ken Herrmann

Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (Abstract #10013)

Nicolas Penel

Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts). (Abstract #10014)

Sophie Cousin

A prognostic nomogram for prediction of recurrence following surgical resection of desmoid tumors. (Abstract #10015)

Aimee Marie Crago

Is CTNNB1 mutational analysis predictive for progression in patients with sporadic desmoid tumors primarily observed? (Abstract #10016)

Chiara Colombo

Desmoid fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. (Abstract #10017)

Marco Fiore
Localized angiosarcomas (AS): Identification of prognostic factors (PF) and analysis of treatment impact—Series from the French Sarcoma Group (GSF/GETO). (Abstract #10018)

Clothilde Lindet

Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications. (Abstract #10019)

Sandra P. D’Angelo

Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangiendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT). (Abstract #10020)

Christine Chevreau

Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers. (Abstract #10021)

Vivek Subbiah

Discussion

Bartosz Chmielowski, MD, PhD

Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors. (Abstract #10022)

Emanuela Palmerini

Advanced chondrosarcomas: Role of chemotherapy and survival. (Abstract #10023)

Binh Bui Nguyen

Cetuximab and EGFR inhibitors in patients with neurological symptoms due to chordoma. (Abstract #10024)

Ola Linden

Establishment of a chordoma xenograft and in vivo testing of compounds identified by high-throughput screening. (Abstract #10025)

Matteo Maria Trucco

Lapatinib in advanced chordoma: A phase II study. (Abstract #10026)

Silvia Stacchiotti

Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): A study from the French Sarcoma Group. (Abstract #10027)

Philippe Alexandre Cassier

Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS). (Abstract #10028)

Rashmi Chugh

Discussion

Francis J Hornicek, MD, PhD
• Immunohistochemical identification of SDHA-mutant gastrointestinal stromal tumors (GISTs). (Abstract #10029)
  Andrew J. Wagner

• Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models. (Abstract #10030)
  Thomas Van Looy

• Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors. (Abstract #10031)
  Peter Hohenberger

• Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST). (Abstract #10032^)
  Sebastian Bauer

• Dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter phase II trial of the SAKK (SAKK 56/07). (Abstract #10033)
  Michael Montemurro

• Discussion
  Christian Frederick Meyer, MD, PhD

**Session Title:** Cancer Prevention/Epidemiology

**Session Type:** General Poster Session

**Time:** 1:15 PM - 5:15 PM

**Location:** S Hall A2

Brd. 1A
• Correlation of breast cancer risk in European BRCA2 mutation carriers with birth cohort. (Abstract #1537)
  Muy-Kheng Maria Tea

Brd. 1B
• Identification of new susceptibility genes in familial breast cancer by exome sequencing. (Abstract #1538)
  Henry T. Lynch

Brd. 1C
• Evaluation of genes associated with undescended testes as predictors of TGCT susceptibility. (Abstract #1539)
  Ariela Marshall

Brd. 1D
• MEN1 gene mutations with different phenotypic presentations in two families: Is it a time to grade MEN1 mutations as high-risk and low-risk? (Abstract #1540)
  Alexander L. Shifrin

Brd. 1E
• Clinical characteristics of patients with malignant pleural mesothelioma (MPM) harboring somatic BAP1 mutations. (Abstract #1541)
  Marjorie Glass Zauderer

Brd. 1F
• Genetic testing referral, uptake, and results in a program for women age 40 or younger with breast cancer. (Abstract #1542)
  Asma Ali
Brd. 1G
• Breast cancer in Irish families with Lynch syndrome. (Abstract #1543)
  Emmet Jordan

Brd. 2A
• Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing. (Abstract #1544)
  Jennifer Madeline Matro

Brd. 2B
• BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer. (Abstract #1545)
  Elena Castro

Brd. 2C
• Comparison of BRCA1/2-positive and -negative women diagnosed with metachronous breast and ovarian cancers. (Abstract #1546)
  Amanda C. Brandt

Brd. 2D
• Features of familiality in a cohort of patients (pts) with sarcoma. (Abstract #1547)
  Georgios Lypas

Brd. 2E
• Analysis of mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples from two phase II clinical trials using a Sequenom-based approach. (Abstract #1548)
  Maria Orr

Brd. 2F
• Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. (Abstract #1549)
  Nisreen Elsayegh

Brd. 2G
• Profiling uptake of single site testing (SST) for familial cancer (CA) risk in an administrative genetic testing database. (Abstract #1550)
  Michael J. Hall

Brd. 3A
• NAD(P)H: Quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: A meta-analysis. (Abstract #1551)
  Yuqing Lou

Brd. 3B
• Ethnic difference of driver mutation frequencies and correlations between driver mutations and histologic subtypes in lung adenocarcinoma. (Abstract #1552)
  Yuki Yamane

Brd. 3C
• Why do breast cancer programs fail to refer patients to genetic counseling upon obtaining family history? (Abstract #1553)
  Julia R. Trosman

Brd. 3D
• Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. (Abstract #1554)
  Grazia Arpino

Brd. 3E
• Variants of uncertain significance in BRCA testing: Impact on risk perception, worry, prevention, and counseling. (Abstract #1555)
  Tracy Graham
• Differential effects of light at night and shift rotation pattern on the circadian system in night workers. (Abstract #1556)
  Pedram Razavi

• A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy. (Abstract #1557)
  Suneetha Puttabasavaiah

• Association of CYP19A1 gene variants with differences in disease progression in breast cancer patients from different racial/ethnic backgrounds. (Abstract #1558)
  Reina Villareal

• Public perception of cancer risk. (Abstract #1559)
  Lisa Burns

• The effects of BR-DIM (BioResponse 3, 3’-Diindolylmethane) administered pre-prostatectomy on the androgen receptor (AR). (Abstract #1560)
  Elisabeth I. Heath

• Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. (Abstract #1561)
  Sangeetha Meda Reddy

• Breast cancer risk reduction among patients with DCIS. (Abstract #1562)
  Melanie R. Palomares

• Risk perception and knowledge of breast and colon cancers in a diverse population. (Abstract #1563)
  Katherine Lang

• First report on screening an asymptomatic population for cancer: The yield of an integrated cancer prevention center. (Abstract #1564)
  Tal Sella

• Factors and trends in cancer screening in the United States from 2004 to 2010. (Abstract #1565)
  Thanyanan Reungwetwattana

• Sun exposure profile in the French population: Results of the EDIFICE melanoma survey. (Abstract #1566)
  Bruno Sassolas

• Cancer screening: Source of information and level of trust. (Abstract #1567)
  Jean F. Morere

• Cancer screening in France: 3rd edition of the EDIFICE survey. (Abstract #1568)
  Jérôme Viguier
• Patient perceptions of stool-based DNA testing across racial groups. (Abstract #1569)
  
  *Lily Huang*

• On-line breath analysis of volatile organic compounds as a method for colorectal cancer detection. (Abstract #1570)
  
  *Francisco Zambrana Tevar*

• The effect of family history on adherence to breast cancer screening guidelines. (Abstract #1571)
  
  *Lauren Marie Hibler*

• ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study. (Abstract #1572)
  
  *Yuksel Urun*

• Esophageal cancer incidence gender disparity. (Abstract #1573)
  
  *Luckson Noe Mathieu*

• Study KBP-2010-CPHG: Characteristics and management of 7,051 new cases of lung cancer managed in French general hospitals in 2010. (Abstract #1574)
  
  *Chrystele Locher*

• Hepatitis B reactivation risk in patients with solid tumors receiving single-agent capecitabine versus doxorubicin-based chemotherapy. (Abstract #1575)
  
  *Winnie Hui Yee Ling*

• Predictors of pediatric and adult fibrosarcoma survival: Analyses of the Surveillance, Epidemiology, and End Results (SEER) program, 1973-2008. (Abstract #1576)
  
  *Simona Ognjanovic*

• Assessing a prognostic model for predicting VTE occurrence in cancer patients. (Abstract #1577)
  
  *Deesha Sarma*

• Incidence of bone metastases among children with cancer in Denmark. (Abstract #1579)
  
  *Rohini Khorana Hernandez*

• Compliance of recommendations with French clinical practice in the management of ThromboEmbolism in patients with cancer: The CARMEN study. (Abstract #1580)
  
  *Marie-Antoinette Sevestre*

• Castration resistance and high-risk disease among nonmetastatic (M0) prostate cancer (PC) patients on androgen deprivation therapy (ADT). (Abstract #1581)
  
  *Melissa Pirolli*

• Age, race/ethnicity, and the ER/PR/HER2 subtypes in breast cancer. (Abstract #1582)
  
  *Carol Parise*
Factors associated with referral to medical oncology (MO) and subsequent use of adjuvant chemotherapy (ACT) among patients with resected non-small cell lung cancer (NSCLC): A population-based study. (Abstract #1583)

Janarthanan Kankesan

Impact of response shift on time to quality-of-life scores deterioration in patients with breast cancer. (Abstract #1584)

Zeinab Hamidou

An exploratory study to determine if BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity. (Abstract #1585)

Roohi Ismail-Khan


Akm Mosharraf Hossain


Myung Mi Cho

Second primary gynecologic neoplasms among breast cancer survivors. (Abstract #1588)

Maria Pilar Barretina Ginesta

The influence of prognostic factors on metastatic breast cancer survival over time. (Abstract #1589)

Margaret Quinn Rosenzweig

Renal impairment after chemotherapy in lung (LC), colorectal (CRC), and breast cancer (BC) patients (pts) from the Henry Ford Health System (HFHS) tumor registry. (Abstract #1590)

Laura Chu

Treatment patterns and comorbidities in a population-based cohort of glioblastoma patients diagnosed 1997-2008. (Abstract #1591)

Susan A. Oliveria

Secondary breast cancer (s-BC) after hematopoietic cell transplantation (HCT) for leukemia: Role of total body irradiation (TBI). (Abstract #1592)

Can-Lan Sun

Effect of sunlight exposure on survival in patients with lymphoma: Results from the prospective Singapore Lymphoma Study. (Abstract #1593)

Yin Leng Lee

Association of a history of autoimmunity or hypersensitivity with overall survival in breast cancer. (Abstract #1594)

Hakan Lars Olsson
• The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. (Abstract #1595)
  
  Brigid K. Killelea

• ABO blood group and the risk of lung cancer: Multicenter, case-control, observational study. (Abstract #1596)
  
  Gungor Utkan

• Association of p53 Arg72Pro polymorphism and HPV status with the initiation, progression, and development of cervical cancer (CC): A meta-analysis. (Abstract #1597)
  
  Steven Habbous

• Analyzing excess mortality from cancer among individuals with mental illness. (Abstract #1598)
  
  Jackson S. Musuuza

• Analysis of KRAS and BRAF mutant colorectal cancers in a multiracial population. (Abstract #1599)
  
  Jared David Acoba

• Correlation of high body mass index and circulating tumor cell positivity in patients with early-stage breast cancer. (Abstract #1600^)
  
  Uta Ortmann

• Evolution and landscape of clinical trials for breast cancer patients. (Abstract #1601)
  
  Semih Dogan

• Correlation of BMI with tumor stage in early breast cancer patients (pts): Pooled analysis of the German SUCCESS A, B, and C trials. (Abstract #1602)
  
  Carola Anna Melcher

• Effect of gender on age-specific effects for ulcerated malignant melanomas. (Abstract #1603)
  
  Blakely S. Richardson

• Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study. (Abstract #1604)
  
  Antongiulio Faggiano

• Survival of elderly Medicare patients after standard chemotherapy for advanced lung and gastrointestinal cancers in the real world. (Abstract #1605)
  
  Elizabeth B. Lamont

• Breast cancer survival: Is the Asian population homogenous? (Abstract #1606)
  
  Vincent Caggiano

• Impact of obesity and overweight in the prognosis of women diagnosed with non metastatic breast cancer in a Mexican cohort. (Abstract #1607)
  
  José Luis Aguilar
American BRCA outcomes and utilization of testing (ABOUT) study. (Abstract #1608)
Rebecca Sutphen

Association between age, gender, residential region, and prevalence of subependymal giant cell astrocytoma among patients with tuberous sclerosis complex: A U.S. Healthcare Claims Database study. (Abstract #1609)
Michael Kohrman

Health and quality of life (QOL) issues in four groups of lung cancer patients: Low-dose computed tomography (LDCT) screened, chest x-ray detected, incidentally found, and routinely diagnosed. (Abstract #1610)
Ping Yang

A retrospective analysis of all non-AIDS defining cancers (NADC): A subset analysis of the County Hospital AIDS Malignancy Project (CHAMP). (Abstract #1611)
Shweta Gupta

The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population. (Abstract #TPS1612)
Thomas Ettrich

Mitigation of iatrogenic risk in young women Hodgkin’s survivors, acceptability of a structured information process. (Abstract #TPS1613)
François Eisinger

Trial of exercise in ovarian cancer survivors. (Abstract #TPS1614)
Melinda Irwin

Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. (Abstract #TPS1615)
Bruce M. Boman

O6-benzylguanine (BG) and temozolomide (TMZ) therapy of glioblastoma multiforme (GBM) with infusion of autologous lentiviral transduced P140KMGMT+ hematopoietic progenitors to protect hematopoiesis: A phase I study. (Abstract #TPS1616)
Andrew E. Sloan

Session Title: Central Nervous System Tumors
Session Type: General Poster Session
Time: 1:15 PM - 5:15 PM
Location: S Hall A2

Does pilocytic astrocytoma (PA) in adults have a different prognosis than PA in children? (Abstract #2038)
Daniel Fernandes Marques

Use of a non-coplanar half-beam block on the lower spinal field to decrease the maximum bowel and cumulative dose in craniospinal irradiation. (Abstract #2039)
Madeera Kathpal
• Relationship of cognitive function, quality of life (QOL), and neuroimaging in primary CNS lymphoma (PCNSL) survivors. (Abstract #2040)
  
  Nancy Diane Doolittle

• Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. (Abstract #2041)
  
  Chae-yong Kim

• The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study. (Abstract #2042)
  
  Analia Azaro

• Expression of CXCR7, CXCR4, CXCR3 and their chemokine ligands in glioblastoma. (Abstract #2043)
  
  Robert D. Berahovich

• Use of tumor-targeting salmonella typhimurium to eradicate human glioma in an orthotopic model in nude mice. (Abstract #2044)
  
  Masashi Momiyama

• A phase II multicentric study of sunitinib administered as upfront therapy in glioblastoma: A study by the GEINO group. (Abstract #2045)
  
  Carmen Balana

• Neuraxis imaging in leptomeningeal metastasis: A retrospective case series. (Abstract #2046)
  
  Marc C. Chamberlain

• The effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02. (Abstract #2047)
  
  Roshan Sudhir Prabhu

• First results of radiotherapy after hyperbaric oxygenation with temozolomide for high-grade gliomas. (Abstract #2048)
  
  David Hamid Khelif

• Predictive role of MGMT status in recurrent glioblastoma (GBM) patients (PTS) treated with antiangiogenic drug (AD) plus temozolomide (TMZ) or CPT-11. (Abstract #2049)
  
  Giuseppe Lombardi

• Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas. (Abstract #2050)
  
  Johnny Duerinck

• Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2051)
  
  Marshall W. Pitz
• Concurrent intrathecal methotrexate and liposomal cytarabine for the treatment of leptomeningeal metastasis from solid tumors. (Abstract #2052)
  
  Brian J. Scott

• Correlation of large brain edema with favorable prognosis in patients with single brain metastases. (Abstract #2053)
  
  Matthias Preusser

• Management of primary intraocular lymphoma (PIOL): Results from the prospective German PIOL registry (PIOL-R). (Abstract #2054)
  
  Kristoph Jahnke

• Effect of the integrin inhibitor cilengitide on TGF-beta signaling. (Abstract #2055)
  
  Michael Weller

• Impaired expression of ketone metabolizing enzymes in malignant gliomas: Implication for ketogenic diet therapy. (Abstract #2056)
  
  Howard T. Chang

• Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register. (Abstract #2057)
  
  Alba Ariela Brandes

• Quality of life in patients with malignant brain tumors. (Abstract #2058)
  
  Ali K. Choucair

• Tolerance and feasibility of chemotherapy by procarbazine, lomustine, and vincristine (PCV) for oligodendroglial anaplastic gliomas (OAG). (Abstract #2060)
  
  Marine Daros

• Anaplastic gliomas at first recurrence: Outcome analysis. (Abstract #2061)
  
  Enrico Franceschi

• The association of pretreatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme (GBM). (Abstract #2062)
  
  Richard Martin Bambury

• Illness intrusiveness and subjective well-being in patients with glioblastoma multiforme. (Abstract #2063)
  
  Linda E. Coate

• Impact of duration of bevacizumab (Bev) treatment in the prognosis of adults with recurrent malignant gliomas. (Abstract #2064)
  
  Mohamed Ali Hamza

• Rising incidence of glioblastoma and meningioma in the United States: Projections through 2050. (Abstract #2065)
  
  Derek Richard Johnson
• A preclinical study on the combined treatment of nimotuzumab and sirolimus in glioblastoma. (Abstract #2066)
  Chee Kian Tham

• Bevacizumab failure in glioblastomas. (Abstract #2067)
  Ghazaleh Tabatabai

• Effect of electrochemotherapy with IV bleomycin on complete response in a preclinical brain tumor study. (Abstract #2069)
  Birgit Agerholm-Larsen

• Prospective follow-up of a cohort of 112 patients with leptomeningeal metastases of breast cancer recruited from 2007 to 2011: Prognostic factors. (Abstract #2070)
  Fahed Zairi

• Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study. (Abstract #2071)
  Birgit Flechl

• Pediatric glioblastoma: Results with adjuvant chemoradiation using temozolomide. (Abstract #2072)
  Nikhil Purushottam Joshi

• Bevacizumab use and central nervous system (CNS) hemorrhage. (Abstract #2073)
  Nathalie LeTarte

• Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). (Abstract #2074^)
  Mary Lou Affronti

• Phase II trial of bevacizumab and fotemustine in recurrent grade III gliomas. (Abstract #2075)
  Riccardo Soffietti

• Adult low-grade gliomas: The Cleveland Clinic experience. (Abstract #2076)
  Lizbeth Robles Irizarry

• Utility of iron oxide nanoparticles in the radiographic diagnosis of CNS lymphoma and inflammatory diseases. (Abstract #2077)
  Brian T. Farrell

• MRI-based vessel function maps for high-resolution differentiation between tumor and nontumoral tissues in brain tumor patients. (Abstract #2078)
  Leor Zach

• Tegwondo-CCNU: A novel combination of protracted, near-continuous temozolomide and CCNU with activity in recurrent malignant gliomas. (Abstract #2079)
  Herwig Matthias Strik
• Retrospective analysis of glioblastoma patients treated with bevacizumab who presented with multifocal disease at diagnosis. (Abstract #2080)  
  Jethro Lisien Hu

• The impact of bevacizumab on the occurrence and recurrence of intracranial brain metastases in non-small cell lung cancer (NSCLC) patients. (Abstract #2081)  
  Mohamed E. Salem

• Relationship between IDH1 mutation status and magnetic resonance imaging features in WHO grade II and III oligodendrogial tumors. (Abstract #2082)  
  Frederique Toulgoat

• Plasma levels of IL-8 and g-CSF in high-grade gliomas treated with bevacizumab. (Abstract #2083)  
  Marica Eoli

• The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma. (Abstract #2084)  
  Jeremy Rudnick

• The role of fluorescence-guided surgical resection in the combined treatment of malignant glioma. (Abstract #2085)  
  Carmine Maria Carapella

• An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM). (Abstract #2086)  
  Max E. Scheulen

• Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine. (Abstract #2087)  
  Surasak Phuphanich

• High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma. (Abstract #2089)  
  Mary Roberta Welch

• The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). (Abstract #2090^)  
  Henry S. Friedman

• Comparison of fractionated and single session radiosurgery for radiation resistant brain metastases. (Abstract #2091)  
  Eric Karl Oermann

• Primary central nervous system lymphoma: The Cleveland Clinic experience. (Abstract #2092)  
  Manmeet Singh Ahluwalia
• Low-grade gliomas in older patients. (Abstract #2093)
  Adewale Alade Fawole

• Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. (Abstract #2094^)
  James J Vredenburgh

• Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. (Abstract #2095^)
  Annick Desjardins

• Prognostic nomogram in elderly patients with glioblastoma. (Abstract #2096)
  Mital Patel

• Poor prognostic factors of post-CNS recurrence survival in breast cancer patients. (Abstract #2097)
  Carlos Castaneda Altamirano

• Effects of laseroid U-74389G liposomes in a glioblastoma mouse model. (Abstract #2098)
  Fady Ibrahim

• Primary CNS lymphoma: A review of clinicopathologic characteristics, therapy, and outcomes of 54 patients with primary CNS DLBCL. (Abstract #2099)
  Nalini Hasija

• Anaplastic oligodendrogial tumors: The Cleveland Clinic experience. (Abstract #2100)
  Neda Hashemi-Sadraei

• Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. (Abstract #2101)
  Daniel Pertschuk

• Correlation between CD4 lymphocytes count and the opportunistic infections in treated glioblastoma. (Abstract #2102)
  Marie Josee Begin

• REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). (Abstract #TPS2103)
  David A. Reardon

• A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). (Abstract #TPS2104)
  James R. Perry

• Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE). (Abstract #TPS2105)
  Ghazaleh Tabatabai
• Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409). (Abstract #TPS2106)
  _Santosh Kesari_

• A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT–107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. (Abstract #TPS2107)
  _Elma S. Hawkins_

**Session Title:** Head and Neck Cancer  
**Session Type:** General Poster Session  
**Time:** 1:15 PM - 5:15 PM  
**Location:** S Hall A2

Brd. 21A
• Longitudinal Oncology Registry of Head and Neck carcinoma (LORHAN): Analysis of African American patients. (Abstract #5533)  
  _David N. Hayes_

Brd. 21B
• Phase II study of biweekly dose-intensive docetaxel plus gemcitabine (GEM/DOC) in patients with recurrent locoregional or metastatic head and neck squamous cell carcinoma. (Abstract #5534)  
  _Ammar Sukari_

Brd. 21C
• An open-labeled, multicentric clinical study of cetuximab combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): A 2-year follow-up report. (Abstract #5535)  
  _Chun-yan Chen_

Brd. 21D
• Gingival cancer: 11 years follow-up at Karolinska University Hospital (2000-2010). (Abstract #5536)  
  _Rusana Simonoska_

Brd. 21E
• Efficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC). (Abstract #5537)  
  _Lauren Quinn Shapiro_

Brd. 21F
• A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma. (Abstract #5538)  
  _Cong Xue_

Brd. 21G
• Patterns of care in elderly patients with squamous cell carcinoma of the head and neck: A SEER-Medicare analysis. (Abstract #5539)  
  _Noam Avraham VanderWalde_

Brd. 21H
• Prevalence, trends, and survival impact of human papillomavirus on oropharyngeal cancer in Indian population. (Abstract #5540)  
  _Ankur Bahl_
• Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5541)
  
  *Prakash Varadarajan*

Brd. 22B

• Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706. (Abstract #5542)

  *Makoto Tahara*

Brd. 22C

• Validation for a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. (Abstract #5543)

  *Xiao-Jun Ma*

Brd. 22D

• A multi-institutional phase II trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. (Abstract #5544)

  *Keith Christopher Bible*

Brd. 22E

• A phase I study of everolimus (E) plus weekly cisplatin (CDDP) plus intensity-modulated radiation therapy (IMRT) in head and neck (HN) cancer. (Abstract #5545^)

  *Matthew G. Fury*

Brd. 22F

• The role of family caregiver in the head and neck cancer: Psychological distress and quality of life evaluation. (Abstract #5546)

  *Mario Airoldi*

Brd. 22G

• Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). (Abstract #5547)

  *Maria E. Cabanillas*

Brd. 22H

• Recurrent/metastatic salivary gland malignancies (RMSGM): Final report of 60 cases treated with cisplatin plus vinorelbine (DDP+VNB). (Abstract #5548)

  *Fulvia Pedani*

Brd. 23A

• Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC). (Abstract #5549)

  *Julie E. Bauman*

Brd. 23B

• Preoperative recombinant adenoviral human p53 gene combined with intensity-modulated radiation therapy in treatment of stage IV papillary thyroid carcinoma: A randomized clinical study. (Abstract #5550)

  *Jingqiang Zhu*

Brd. 23C

• Association of smoking status with p16 and cyclin D1 (CCND1) expression with clinical characteristics and overall survival (OS) in oropharyngeal squamous cell carcinoma (OSC). (Abstract #5551)

  *Mei-Kim Ang*
• Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (Abstract #5552)
  
  Yoojoo Lim

• The accuracy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in the staging of newly diagnosed nasopharyngeal carcinoma: A systematic review and meta-analysis. (Abstract #5553)
  
  Balamurugan A. Vellayappan

• Expression and prognostic significance of directed therapy targets and mutational analysis of the EGFR pathway in malignant salivary gland tumors. (Abstract #5554)
  
  Jerome F Cros

• Association between salivary cytokine levels and chemoradiotherapy-induced toxicities in head and neck cancer patients. (Abstract #5555)
  
  Paolo Bossi

• Organ preservation with daily concurrent chemoradiotherapy using a new superselctive intra-arterial infusion for stage III, IV tongue cancer. (Abstract #5556)
  
  Iwai Tohnai

• Gemcitabine versus cisplatin concurrent with radiation therapy in locally advanced head and neck squamous cell carcinoma. (Abstract #5557)
  
  Magda Mostafa

• Recombinant adenoviral human p53 gene combined with radio- and chemotherapy in treatment of advanced nasopharyngeal carcinoma: A randomized clinical study. (Abstract #5558)
  
  Guiping Lan

• Outcomes of occult primary (OP) of the head and neck squamous cell carcinoma (HNSCC) treated with oropharynx (OPX) targeted radiotherapy (RT) and concurrent chemotherapy (CCRT). (Abstract #5559)
  
  Kenneth Hu

• Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5560)
  
  Nabil F. Saba

• Patient-reported symptoms following IMRT alone for oropharynx cancer: A survivorship study. (Abstract #5561)
  
  Gary Brandon Gunn

• Nomogram for prediction of prognosis in patients treated for oral cavity squamous cell carcinoma. (Abstract #5562)
  
  Pablo H. Montero

• Head and neck cancer in Fanconi anemia and dyskeratosis congenita. (Abstract #5563)
  
  Blanche P Alter
• Should age affect our treatment decisions for head and neck cancer? (Abstract #5564)
  Estrella M. Carballido

• EGFR-KRAS genotyping and EGFR-CDX2 expression in sinonasal intestinal type adenocarcinomas: Toward a new targeted therapy? (Abstract #5565)
  Olivier Choussy

• ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). (Abstract #5566)
  Shanthi Marur

• Young adults with squamous cell head and neck cancer: Ten years of a single institution’s experience (1999-2008). (Abstract #5567)
  Marcos Pantarotto Alves

• Feasibility and short-term efficacy of four facio-cervical fields’ conformal radiotherapy for nasopharyngeal carcinoma. (Abstract #5568)
  Wang fang Zheng

• Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study. (Abstract #5569)
  Marie-Helene Massicotte

• Paranasal sinus squamous cell carcinomas (PNSSCC) incidence and survival trends. (Abstract #5570)
  Benjamin Ansa

• Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02. (Abstract #5571)
  Jolie Ringash

• Correlation between PI3K/PTEN/AKT/mTOR pathway genetic variations and clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. (Abstract #5572)
  Alberto Fusi

• Correlation of microbiomic profiles with disease status and MDR1 methylation in head and neck squamous cell carcinoma (HNSCC). (Abstract #5573)
  Pauline Funchain

• Genetic alterations in HRAS gene in relation to outcome and response to cetuximab in head and neck squamous cell carcinoma. (Abstract #5574)
  Theodoros Rampias

• Identification of head and neck cancers (SCCHN) that may respond to dual inhibition of EGFR and HER3 signaling. (Abstract #5575)
  David S. Shames
• Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). (Abstract #5576)
  
  Amanda Psyrri

• The impact of advanced age on outcomes in squamous cell carcinoma of the head and neck. (Abstract #5577)
  
  Virginia Ann Moye

• A combined evaluation strategy of FDG PET/CT and contrast-enhanced diagnostic CT (ceCT) for lymph nodes in the neck. (Abstract #5578)

  Neetha Gandikota

• A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT for locally advanced squamous cancer of the head and neck (LASCCHN). (Abstract #5579)

  Roy B. Tishler

• P16 and cyclin D1 (CYD1) as prognostic markers in hypopharyngeal (HSC) and oropharyngeal squamous cell carcinoma (OSC). (Abstract #5580)

  Siok Hoon Ang

• The role of post-operative radiotherapy (PORT) in the management of parotid gland malignancy (PGM). (Abstract #5581)

  Louis Benjamin Harrison

• HPV and survival in patients with oropharyngeal squamous cell cancer of the head and neck (OPC) treated with induction chemotherapy followed by chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): The Dana-Farber experience. (Abstract #5582)

  Jochen H. Lorch

• Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation (XRT) in recurrent squamous cell carcinoma of the head and neck (SCCHN): Long-term follow-up of Radiation Therapy Oncology Group (RTOG) protocol 9911. (Abstract #5583)

  Corey J. Langer

• Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma. (Abstract #5584)

  Hiroyuki Goda

• Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus. (Abstract #5585)

  Vijay Patil

• Importance of HPV involvement and FOXP3+ T-cell status as prognostic factors in tonsilar squamous cell carcinoma. (Abstract #5586)

  Kwonoh Park

• Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort. (Abstract #5587)

  Albiruni Ryan Abdul Razak
• Second primary tumors in head and neck squamous cell carcinoma patients: A cross-sectional study. (Abstract #5588)
  
  Luciana Garcia Landeiro

• Pattern of symptoms in head and neck cancer (HNC) survivors treated with radiation therapy (RT): Association with systemic therapy. (Abstract #5589)
  
  David Ira Rosenthal

• Gene expression as a predictor of radiotherapy or chemoradiotherapy response in head and neck squamous cell carcinoma patients: A molecular approach. (Abstract #5590)
  
  Antonio Lopez-Pousa

• A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). (Abstract #5591)
  
  Martin Schlumberger

• Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). (Abstract #5592)
  
  George R. Blumenschein

• TPF induction chemotherapy and pathologic response for patients with locally advanced and resectable oral squamous cell carcinoma. (Abstract #5593)
  
  Lai-ping Zhong

• Long-term survival after distant metastasis in oropharyngeal carcinoma. (Abstract #5594)
  
  Sean M McBride

• Progressive increasing in the risk of second and subsequent malignant tumors in patients with a head and neck cancer: A validation study with SEER data. (Abstract #5595)
  
  Xavier Leon

• Contralateral parotid volume as an objective marker for adaptive radiotherapy in head and neck cancer. (Abstract #5596^)
  
  Patrick James Gagnon

• Clinical outcomes and prognostic factors of 582 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. (Abstract #5597)
  
  Jin Yi Lang

• LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy. (Abstract #TPS5598)
  
  Jean-Pascal H. Machiels

• LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. (Abstract #TPS5599)
  
  Barbara Burtness
A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). (Abstract #TPS5600)

John N Waldron

Phase II trial of neoadjuvant chemotherapy for HPV-associated squamous cell carcinoma of the oropharynx followed by reduced-dose radiotherapy/chemoradiotherapy for responders or standard dose chemoradiotherapy for nonresponders. (Abstract #TPS5601)

Bhoomi Mehrotra

A pilot study of raltegravir and cisplatin in head and neck squamous cell carcinoma (HNSCC). (Abstract #TPS5602)

Julie E. Bauman

Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session Type: General Poster Session
Time: 1:15 PM - 5:15 PM
Location: S Hall A2

Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small cell lung cancer. (Abstract #7034)

Si-Yu Wang


David Michael Waterhouse

Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer. (Abstract #7036)

Nan Du

A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer. (Abstract #7039)

Wenzhao Zhong

Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. (Abstract #7040)

Julia Shelkey

Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology. (Abstract #7041)

Alex Martinez Marti

A phase II study of cisplatin (P), S-1 (S), and concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0501. (Abstract #7042)

Daizo Kishino
Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. (Abstract #7043)

Feiran Lou

Higher incidence of EGFR exon 19 deletion in younger (age 40 or younger) patients with adenocarcinoma of the lung. (Abstract #7044)

Eri Sugiyama

A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial. (Abstract #7045)

Akiko Hisamoto

Molecular profiling of patients with non-small cell lung cancer (NSCLC) using bronchoscopic ultra-micro sampling. (Abstract #7046)

Yuichi Sakairi

Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. (Abstract #7047)

Jianjun Zhang

Breath analysis for early detection of lung cancer. (Abstract #7048)

Geetha D. Vallabhaneni

Outcomes of combined modality treatment in elderly patients with stage III non-small cell lung cancer. (Abstract #7049)

Ludimila Cavalcante

Case-control study of prophylactic cranial irradiation in nonmetastatic non-small cell lung cancer. (Abstract #7050)

Simon Cheng

Correlation of pretreatment surgical staging and PET SUVmax with outcomes in NSCLC. (Abstract #7051)

Giancarlo Moscol

5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial. (Abstract #7052)

Alexander Edward Dela Cruz Drilon

High-throughput targeted resequencing of lung adenocarcinoma. (Abstract #7053)

Byung Chul Kim

Are the presenting characteristics and prognosis of primary salivary gland-type lung cancers (SG) similar to those of other non-small cell lung cancers (NSCLC)? (Abstract #7054)

John M. Varlotto
• Would screening benefit 75- to 84-year-old patients with non-small cell lung cancer (NSCLC)? (Abstract #7055)
  *Jessica Lake*

• Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC). (Abstract #7056)
  *Albert Linder*

• Prognostic value of pathologic complete response to preoperative chemotherapy in early-stage non small cell lung cancer: Combined analysis of two IFCT randomized trials. (Abstract #7057)
  *Guillaume Mouillet*

• Prognostic role of FOXP3/CD4 ratio in resectable NSCLC. (Abstract #7058)
  *Marta Usó*

• A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer. (Abstract #7059)
  *Madhusmita Behera*

• miRNA profiling in resectable NSCLC by multiplex next-generation sequencing. (Abstract #7060)
  *Sandra Gallach*

• SOX2 and FGFR1 gene copy number in surgically resected non-small cell lung cancer (NSCLC). (Abstract #7061)
  *Luca Toschi*

• Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer in the elderly. (Abstract #7062)
  *Shervin Mohajer Shirvani*

• FGFR1 amplification in squamous cell lung cancers. (Abstract #7063)
  *Michele L Cote*

• Survival following segmentectomy and lobectomy for stage I non-small cell lung cancer. (Abstract #7064)
  *Cardinale B. Smith*

• Phase II study of concurrent cetuximab (C225) plus definitive thoracic radiotherapy (XRT) followed by adjuvant docetaxel in poor prognosis patients with locally advanced non-small cell lung cancer (LA-NSCLC). (Abstract #7065)
  *Thomas J. Dilling*

• Prospective study of tumor suppressor gene (TSG) methylation as a prognostic biomarker in surgically resected non-small cell lung cancer (NSCLC). (Abstract #7066)
  *Christopher G. Azzoli*
• Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS). (Abstract #7067)

  Marta Batus

• Phase II trial: Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer patients. (Abstract #7068)

  Dolores De la Mata

• Mediastinal lymph node examination and survival in resected early-stage non-small cell lung cancer in the Surveillance, Epidemiology, and End Results (SEER) database. (Abstract #7069)

  Raymond U Osarogiagbon

• Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). (Abstract #7070)

  Hidehito Horinouchi

• Anatomic segmentectomy versus lobectomy for clinical stage I non-small cell lung cancer: A propensity-matched analysis. (Abstract #7071)

  Matthew J. Schuchert

• Size distribution and metastasis in discarded intrapulmonary lymph nodes (LN) after lung cancer resection. (Abstract #7072^)

  Laura Elizabeth Miller

• N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). (Abstract #7073)

  Steven E. Schild

• Factors influencing recurrence following anatomic lung resection for non-small cell lung cancer. (Abstract #7074)

  Rodney Jerome Landreneau

• The Lung Cancer Symptom Scale (LCSS) as a prognostic indicator of overall survival in malignant pleural mesothelioma (MPM) patients: Post hoc analysis of a phase III study. (Abstract #7075)

  Ping Wang

• NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM). (Abstract #7076)

  Gilda Rossoni

• Phase II trial of anti-transforming growth factor-beta (TGFß) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM). (Abstract #7077)

  James Stevenson
Elevated PDGFRB gene copy number gain as prognostic in resected malignant pleural mesothelioma. (Abstract #7078)

Anne S. Tsao

Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration. (Abstract #7079^)

Anna K. Nowak

Circulating tumor cell (CTC) as a significant clinical marker in epithelioid-type malignant pleural mesothelioma (MPM). (Abstract #7080)

Kazue Yoneda

Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. (Abstract #7081)

Mary O’Brien

Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey. (Abstract #7082)

Federica Grosso

SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). (Abstract #7083)

Linda L. Garland

Outcomes of sarcomatoid malignant pleural mesothelioma, a distinct clinical entity. (Abstract #7084)

Elisabetta Gattoni

NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC). (Abstract #7085)

Raffaele Cavina

Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802. (Abstract #7086)

Ryota Saito

Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution. (Abstract #7087)

Myles Nickolich

Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. (Abstract #7088)

Kazushige Wakuda

Genome-wide association study of survival in small cell lung cancer patients treated with irinotecan and cisplatin chemotherapy. (Abstract #7089)

Ji-Youn Han
Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC). (Abstract #7090)

Oleg Gladkov

Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392). (Abstract #7091)

Shun Lu

Circulating tumor cells (CTCs) in patients (pts) with small cell lung cancer (SCLC) as a marker of disease burden and therapeutic response, and predictor of disease relapse. (Abstract #7092)

Anjana Ranganathan

NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC). (Abstract #7093)

Peter Michael Ellis

A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). (Abstract #7094)

Christine Marie Lovly

ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results. (Abstract #7095)

Bartomeu Massuti

Investigation of PARP1 as a therapeutic target in small cell lung cancer. (Abstract #7096)

Lauren Averett Byers

Comparison of treatment patterns, health care utilization, and direct costs in elderly patients with distant-stage small cell lung cancer (SCLC) versus non-small cell lung cancer (NSCLC) using the SEER-Medicare database. (Abstract #7101)

Sudeep Karve
• Incidence of venous thromboembolism in lung cancer and its effect on survival. (Abstract # 7102)
  Mohammad Mozayen

• A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies. (Abstract #7103)
  Anish Thomas

• A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. (Abstract #7104)
  Silvia Park

• Neoadjuvant treatment of primary inoperable or local recurrent thymoma with octreotide LAR to improve tumor resectability. (Abstract #7105)
  Berthold Schalke

• Factors affecting survival of patients with Masaoka stage IV thymic epithelial tumors (TET). (Abstract #7107)
  Yaman Suleiman

• Factors influencing outcome in thymic epithelial tumors (TET). (Abstract #7108)
  Ryan Frederick Porter

• International tailored chemotherapy adjuvant trial: Itaca trial. (Abstract #TPS7109)
  Silvia Novello

• Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer harboring activating EGFR mutation (WJOG6410L). (Abstract #TPS7110)
  Hirohito Tada

• Postoperative follow-up of lung cancer: Randomized trial comparing two follow-up programs in completely resected non-small cell lung cancer (IFCT-03O2). (Abstract #TPS7111)
  Virginie Westeel

• IFT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM). (Abstract #TPS7112)
  Gerard Zalcman

  David R. Spigel

**Session Title:** Lung Cancer - Non-small Cell Metastatic
General Poster Session
Location: S Hall A2

**Session Type:** General Poster Session

**Time:** 1:15 PM - 5:15 PM

**Location:** S Hall A2

- **Brd. 44A**
  - Association of epithelial to mesenchymal transition with efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild type. (Abstract #7535)
    - Shengxiang Ren

- **Brd. 44B**
    - Joachim Von Pawel

- **Brd. 44C**
  - Intratumoral heterogeneity of EGFR mutation and clinical significance in Chinese patients with advanced non-small cell lung cancer. (Abstract #7537)
    - Hua Bai

- **Brd. 44E**
    - Simon Ekman

- **Brd. 44F**
  - Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. (Abstract #7540)
    - Enric Carcereny Costa

- **Brd. 44G**
  - A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7541)
    - Hongbin Chen

- **Brd. 44H**
  - Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study. (Abstract #7542)
    - Cristina Buges

- **Brd. 45A**
  - Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). (Abstract #7543)
    - Edward B. Garon

- **Brd. 45B**
  - GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC. (Abstract #7544)
    - James F. Spicer

- **Brd. 45C**
  - FGFR1 amplification and EGFR mutation in Chinese squamous cell lung cancer. (Abstract #7545)
    - Zhigang Wei
A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression. (Abstract #7546)

Martin J. Edelman

Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. (Abstract #7547)

Geoffrey R. Oxnard

A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. (Abstract #7548)

Li Zhang

Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC): Asian subgroup analysis. (Abstract #7549)

Yukito Ichinose

Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). (Abstract #7550)

Cesare Gridelli

A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non Small cell lung cancer (NSCLC). (Abstract #7551)

Chandra Prakash Belani

Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. (Abstract #7552)

Philip C. Mack

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. (Abstract #7553)

Mizuki Nishino

Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7554)

Gerald Schmid-Bindert

N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2). (Abstract #7555)

Grace K. Dy

Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib. (Abstract #7556)

Lecia V. Sequist
• Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy. (Abstract #7557)
  
  *Martin H. Schuler*

Brd. 46H

• Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial. (Abstract #7558)
  
  *Joo-Hang Kim*

Brd. 47A

• Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. (Abstract #7559)
  
  *Yan Sun*

Brd. 47B

• A randomized phase III study of a cisplatin (CDDP) and docetaxel (DOC) with or without irinotecan (CPT) in pts with advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 trial. (Abstract #7560)
  
  *Toshiaki Okada*

Brd. 47C

• A phase II study of erlotinib monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have never/light smoking history: NEJ006/TCOG0903. (Abstract #7561)
  
  *Yoshiki Ishii*

Brd. 47E

• First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies. (Abstract #7563)
  
  *Sodai Narumi*

Brd. 47F

• Elderly and younger patients with non-small cell lung cancer (NSCLC) derive similar benefit from second-line chemotherapy: A retrospective subset analysis of second-line chemotherapy trials conducted from the Hellenic Cooperative Research Group (HORG). (Abstract #7564)
  
  *Sofia Agelaki*

Brd. 47G

• Randomized phase II trial of carboplatin combined with weekly paclitaxel (CP) and docetaxel alone (D) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): NJLCG 0801. (Abstract #7565)
  
  *Shunichi Sugawara*

Brd. 47H

• Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC). (Abstract #7566)
  
  *Bhumsuk Keam*

Brd. 48B

• A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients. (Abstract #7568)
  
  *Leora Horn*
Brd. 48C
- Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced non-small cell lung cancer. (Abstract #7569)

Hiroaki Senju

Brd. 48D
- Older patient participation in SWOG lung cancer trials: Comparative analysis from 1993 to 2008. (Abstract #7570)

Paul Joseph Hesketh

Brd. 48E
- Phase II study of amrubicin (AMR) for patients (pts) with non-small cell lung cancer (NSCLC) as third-line or fourth-line chemotherapy: Hokkaido Lung Cancer Clinical Study Group trial (HOT) 0901. (Abstract #7571)

Toshiyuki Harada

Brd. 48F
- Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. (Abstract #7572)

Martin Faehling

Brd. 48G
- Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival. (Abstract #7573)

Roman Perez-Soler

Brd. 48H
- Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. (Abstract #7574)

Olivier Bylicki

Brd. 49A
- Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results. (Abstract #7575)

Jaafar Bennouna

Brd. 49B
- Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience. (Abstract #7576)

Yuka Kato

Brd. 49C
- The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line. (Abstract #7577)

Francesco Grossi

Brd. 49D
- KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial. (Abstract #7578)

Yoshiyuki Suehara
Family history of lung cancer in never smokers with non-small cell lung cancer (NSCLC) and its association with tumors harboring epidermal growth factor receptor (EGFR) mutations. (Abstract #7579)

Elizabeth Mary Gaughan

Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers. (Abstract #7580)

Anna M. Varghese

NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC). (Abstract #7581)

Vanessa Gregorc

Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy. (Abstract #7582)

David R. Gandara

Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study. (Abstract #7583)

Marianne Nicolson

A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7584)

Eugene Henry Paschold

Expression of folate pathway regulators and pemetrexed (pem) activity in patients (pts) with advanced non-small cell lung cancer (NSCLC). (Abstract #7585)

Letizia Gianoncelli

Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. (Abstract #7586)

Sinead Cuffe

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). (Abstract #7587)

Victor Gian

Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy. (Abstract #7588)

Mohit Butaney

ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. (Abstract #7589)

Marileila Varella-Garcia
• Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). (Abstract #7590)
  
  Mark A. Socinski

• EML4-ALK-gene rearrangements comparative analysis in circulating tumor cells and in tumor tissue of patients with lung adenocarcinoma. (Abstract #7591)
  
  Marius Ilie

• Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). (Abstract #7592)
  
  Markus Frederic Renschler

• Frequency of anaplastic lymphoma kinase (ALK) positive tumors among African American non-small cell lung cancer (NSCLC) patients. (Abstract #7593)
  
  Shirish M. Gadgeel

• Update on the large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. (Abstract #7594)
  
  Tianhong Li

• Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy. (Abstract #7595)
  
  Anna K. Brady

• Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. (Abstract #7596)
  
  Ravi Salgia

• Insulin-like growth factor 1 (IGF-1R) protein expression (PE) and gene copy number (GCN) for discrimination of response and outcome to figitumumab in NSCLC. (Abstract #7597)
  
  Murry W. Wynes

• Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC). (Abstract #7598)
  
  Patrick Schnell

• A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). (Abstract #7599)
  
  Giorgio Scagliotti

• Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (Abstract #7600)
  
  Gregory Alan Otterson

• Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK+ NSCLC). (Abstract #7601)
  
  Eamon Berge
• A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC. (Abstract #7602)

  Katsuyuki Kiura

• MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. (Abstract #7603)

  Matthias Scheffler

• Meta-analysis of progression-free survival as a predictor of overall survival in locally advanced or metastatic non-small cell lung cancer trials. (Abstract #7604)

  Evadne Jane Turner

• Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer. (Abstract #7605)

  Sumithra J. Mandrekar

• Three-year survival in stage IV non-small cell lung cancer (NSCLC): The importance of metastatic distribution. (Abstract #7608)

  Daniel D. Karp

• Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies: Non-small cell lung cancer, small cell lung cancer and thymic malignancies (CUSTOM). (Abstract #TPS7609)

  Ariel Lopez-Chavez

• TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). (Abstract #TPS7610)

  Elisabeth A. Quoix

• CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. (Abstract #TPS7611)

  Martin Reck
• AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT). (Abstract #TPS7612)

Cesare Gridelli

• The GALAXY Trial(NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIB or IV NSCLC. (Abstract #TPS7613^)

Glenwood D. Goss

• ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (Abstract #TPS7614)

Keunchil Park

• ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study. (Abstract #TPS7615)

Michael J. Boyer

• The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). (Abstract #TPS7616)

David R. Spigel

• Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (ProACT). (Abstract #TPS7617)

Amanda Tufman

• Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms. (Abstract #TPS7618)

Vera Hirsh

• A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC). (Abstract #TPS7619)

George R. Simon

---

**Session Title:** American Cancer Society Award and Lecture

**Session Type:** Special Session

**Time:** 3:00 PM - 4:15 PM

**Location:** S100a

**Reducing Breast Cancer Risk: Progress Toward Resolution**

*Rowan T. Chlebowski, MD, PhD*

---

**Session Title:** ASCO/Radiological Society of North America (RSNA) Joint Session: New and Upcoming Techniques in Interventional Radiology in Oncology

**Session Type:** Special Session

**Time:** 3:00 PM - 4:15 PM

**Location:** E353
• Opening Remarks
  
  Sarah S. Donaldson, MD (Co-Chair)

• Digital Tomosynthesis of the Breast
  
  Mark Helvie, MD

• Interventional Oncology of the Liver
  
  Jean-Francois Geschwind, MD

• Closing Remarks
  
  Michael Paul Link, MD (Co-Chair)

---

**Session Title:** Mechanisms of Resistance to Targeted Anticancer Agents  
**Session Type:** Education Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** S406

- Mechanisms of Resistance to Map Kinase Pathway Inhibition in Melanoma
  
  Levi A. Garraway, MD, PhD (Chair)

- Mechanisms of Resistance to Anti-EGFR Therapies in Colorectal Cancers
  
  Alberto Bardelli, PhD

- Mechanisms of Resistance to Targeted Therapies in AML and CML
  
  Neil P. Shah, MD, PhD

- Mechanisms of Resistance to Targeted Agents in Lung Cancer
  
  Alice Tsang Shaw, MD, PhD

---

**Session Title:** Personalized Medicine in Lung Cancer in 2012  
**Session Type:** Education Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E Hall D2

- Treatment and Clinical Trial Design in the Era of Personalized Medicine
  
  Pasi A. Janne, MD, PhD (Chair)

- The Role of Molecular Pathology in the Treatment of Lung Cancer
  
  Ignacio I. Wistuba, MD

- The Role of the Surgeon in Personalized Medicine for Lung Cancer
  
  Tetsuya Mitsudomi, MD, PhD

---

**Session Title:** Interpreting the Colorectal Cancer Pathology Report: New and Potentially Overlooked Information - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E451a

- Interpreting the Colorectal Cancer Pathology Report: What's New and What Are We Missing?
  
  John M. Jessup, MD

---

**Session Title:** Clinically Challenging Cases in Acute Myeloid Leukemia - Ticketed Session  
**Session Type:** Clinical Problems in Oncology Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E451b

- Acute Promyelocytic Leukemia and Core Binding Factor Acute Myeloid Leukemia
  
  Dan Douer, MD (Chair)

- High-Risk Acute Myeloid Leukemia
  
  Richard A. Larson, MD

- Acute Myeloid Leukemia in Older Adults
  
  B. Douglas Smith, MD

---

**Session Title:** Staying Bold while Old
**Session Type:** Clinical Science Symposium  
**Time:** 3:00 PM - 4:30 PM  
**Location:** S100bc

- Co-Chair  
  *William Dale, MD, PhD*

- Co-Chair  
  *Stuart M. Lichtman, MD*

- Physical activity participation and functional limitations in geriatric cancer survivors. (Abstract #9009)  
  *Lisa Sprod*

- EXCAP exercise to improve fatigue, cardiopulmonary function, and strength: A phase II RCT among older prostate cancer patients receiving radiation and androgen deprivation therapy. (Abstract #9010)  
  *Karen Michelle Mustian*

- Discussion  
  *Wendy Demark-Wahnefried, PhD, RD*

- Correlation of short telomeres (ST) with vulnerability, toxicity, and early death in elderly AOC patients receiving carboplatin: A multicenter GINECO trial. (Abstract #9011)  
  *Claire Falandry*

- Prognostic factors of the loss of autonomy (LoA) in older patients with cancer receiving first-line chemotherapy. (Abstract #9012)  
  *Pierre-Louis Soubeyran*

- Discussion  
  *Arti Hurria, MD*

---

**Session Title:** Gastrointestinal (Noncolorectal) Cancer  
**Session Type:** Oral Abstract Session  
**Time:** 3:00 PM - 6:00 PM  
**Location:** E Hall D1

- Co-Chair  
  *Colin D. Weekes, MD, PhD*

- Co-Chair  
  *Abby B. Siegel, MD, MS*

- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). (Abstract #LBA4000)  
  *Tom Samuel Waddell*

- Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. (Abstract #LBA4001)  
  *Emilio Bajetta*

  Brd. 16

- Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. (Abstract #4002)  
  *Shinya Ueda*

- Discussion  
  *Barbara Burtness, MD*
• Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (Abstract #LBA4003)
  Thierry Conroy
• Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/SFU in squamous cell carcinoma of the anus: Results of ACT II. (Abstract #4004)
  Robert Glynne-Jones
• Discussion
  Theodore S. Hong, MD

Brd. 17
• Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. (Abstract #4005)
  Kelly S. Oliner

Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). (Abstract #4006)
  Lorenza Rimassa

• Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). (Abstract #4007)
  Chris Verslype

• A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. (Abstract #4008)
  Zhenggang Ren
• Discussion
  Jordan Berlin, MD

---

Session Title: Genitourinary Cancer (Nonprostate)
Session Type: Oral Abstract Session
Time: 3:00 PM - 6:00 PM
Location: E Arie Crown Theater

• Co-Chair
  Carsten Bokemeyer, MD

• Co-Chair
  Peter C. Black, MD

• Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). (Abstract #4500)
  Naomi B. Haas

• Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. (Abstract #4501)
  Robert John Motzer

• Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. (Abstract #CRA4502)
  Bernard J. Escudier

• Discussion
  Tim Eisen, PhD
• Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. (Abstract #4503)  
  
  Brian I. Rini

• Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). (Abstract #4504)  
  
  Toni K. Choueiri

• Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (Abstract #4505)  
  
  David F. McDermott

• Discussion  
  Lauren Christine Harshman, MD

• Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). (Abstract #4506)  
  
  Petros Grivas

• Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC). (Abstract #4507)  
  
  Andrea Necchi

• Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. (Abstract #4508)  
  
  Torgrim Tandstad

• Discussion  
  Darren Richard Feldman, MD

---

**Session Title:** Gynecologic Cancer  
**Session Type:** Oral Abstract Session  
**Time:** 3:00 PM - 6:00 PM  
**Location:** E354b

• Co-Chair  
  Gottfried E. Konecny, MD

• Co-Chair  
  Don S. Dizon, MD

• Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (Abstract #LBA5000)  
  
  Ignace B. Vergote

• Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. (Abstract #5001)  
  
  Amit M. Oza

• AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) (Abstract #LBA5002^)  
  
  Eric Pujade-Lauraine

• Discussion  
  Michael Seiden, MD, PhD

• Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. (Abstract #5003)  
  
  Noriyuki Katsumata

• Prospective assessment of cost, morbidity, and survival associated with lymphadenectomy in low-risk endometrial cancer. (Abstract #5004)  
  
  Sean Christopher Dowdy
• Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study. (Abstract #5005)
  Nikolaus De Gregorio
• Discussion
  Jonathan S. Berek, MD
• A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCG0505). (Abstract #5006)
  Ryo Kitagawa
• Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study. (Abstract #5007)
  Sven Mahner
Brd. 13
• Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up. (Abstract #5008)
  Kristina Lindemann
• Discussion
  Patricia J. Eifel, MD

**Session Title:** Health Services Research

**Session Type:** Oral Abstract Session

**Time:** 3:00 PM - 6:00 PM

**Location:** S404

• Co-Chair
  Christopher Ryan Friese, RN, PhD
• Co-Chair
  Tunghi May Pini, MD, MPH
• Racial disparities in breast cancer survival. (Abstract #6000)
  Jeffrey H. Silber
• Competing causes of mortality in long-term survivors of head and neck cancer. (Abstract #6001)
  Shrujal S. Baxi
• An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites. (Abstract #6002)
  Chantal Quinten
• Discussion
  Alok A. Khorana, MD
• Regional variation in Medicare spending and survival among older adults with advanced cancer. (Abstract #6003)
  Gabriel Brooks
• Effect of early palliative care on health care costs in patients with metastatic NSCLC. (Abstract #6004)
  Joseph A. Greer
• Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). (Abstract #6005)
  Henrique Hon
• Discussion
  Gary H. Lyman, MD, MPH
• A comparison of primary care providers’ and oncologists’ preferences for different models of cancer survivorship care. (Abstract #6006)
  Winson Y. Cheung
• Who gets a referral to oncologists and subsequent treatments for stages III and IV non-small cell lung cancer (NSCLC)? (Abstract #6007)
  Bernardo Haddock Lobo Goulart
• Oncologists’ and primary care providers’ awareness of late effects of cancer treatment: Implications for survivorship care. (Abstract #6008)
  Larissa Neklyudov
• Discussion
  Jennifer Elston-Lafata, PhD

**Session Title:** Lymphoma

**Session Type:** Oral Abstract Session

**Time:** 3:00 PM - 6:00 PM

**Location:** E354a

• Co-Chair
  Arash A. Alizadeh, MD, PhD

• Co-Chair
  Julie Vose, MD

• CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. (Abstract #8000)
  John Leonard

• A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. (Abstract #8001)
  Oliver W. Press

• Discussion
  Christopher Flowers, MD, MS

• ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. (Abstract #8002)
  Patrice P. Carde

• Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496). (Abstract #8003)
  Jennifer Ann Kanakry

• Discussion
  Laurie Helen Sehn, MD, MPH

• High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. (Abstract #8004)
  Bertram Glass

• A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes. (Abstract #8005)
  Stefan K. Barta

• R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). (Abstract #8006)
  Massimo Federico

• A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. (Abstract #8007)
  Michael E. Williams
• Discussion
   Robert Marcus, MBBS

**Session Title:** Advances in Infection Management in Pediatric Oncology
**Session Type:** Education Session
**Time:** 4:45 PM - 6:00 PM
**Location:** S504

- Options for Early Treatment of Pediatric Cancer Patients with Febrile Neutropenia
  Lillian Sung, MD, PhD
- Treatment of Pediatric Cancer Patients with Common Viral Infections
  Theoklis Zaoutis, MD
- Management Issues for Prolonged Febrile Neutropenia in the Pediatric Cancer Patient
  Andrew Y. Koh, MD (Chair)

**Session Title:** Antiemetics: Current Standards, Emerging Approaches, and Persistent Gaps
**Session Type:** Education Session
**Time:** 4:45 PM - 6:00 PM
**Location:** S100bc

- Incidence and Prevalence of Nausea and Vomiting: Identify Knowledge Gaps in the Management
  Steven M. Grunberg, MD
- Summary of Standard Therapy for the Management of Nausea and Vomiting and Review of Newer Approved Therapies
  Ethan M. Basch, MD, MSc (Chair)
- A Critical Review of the Research with Natural Products and Nonpharmacologic Interventions for Nausea and Vomiting Management
  Rebecca Anne Clark-Snow, RN
- The Barriers Related to Implementing Antiemetic Guidelines into Practice, Including Cost and Drug Availability
  Matti S. Aapro, MD

**Session Title:** Managing Carcinoid Tumors - Ticketed Session
**Session Type:** Meet the Professor Session
**Time:** 4:45 PM - 6:00 PM
**Location:** E451a

- How Do We Manage Carcinoid Tumors?
  Emily K. Bergsland, MD

**Session Title:** Multidisciplinary Management of Unusual Head and Neck Tumors - Ticketed Session
**Session Type:** Clinical Problems in Oncology Session
**Time:** 4:45 PM - 6:00 PM
**Location:** E451b

- Case Presentation of Medullary Thyroid Cancer
  Robert I. Haddad, MD
- Case Presentation of a Salivary Gland Tumor
  Louis Benjamin Harrison, MD (Chair)
- Case Presentation of a Skin Tumor
  Joseph A Califano, MD